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ABSTRACT 
The objectives of this thesis were to assess the objective, clinical, and sexual outcomes 
after transvaginal surgery for pelvic organ prolapse using a trocar guided mesh kit, to 
ascertain the vaginal in vivo histological inflammatory response to large mesh, and to 
identify possible risk factors associated with exposures after transvaginal mesh surgery. 
A prospective multicenter cohort study was performed between June 2006 and 
March 2007 throughout 26 clinics in the Nordic countries. The 261 women included 
underwent pelvic organ prolapse surgery with the Prolift® mesh kit and were examined 
at baseline, two months and one year regarding objective anatomic prolapse stage, signs 
of vaginal inflammation and subjective symptom assessment. We found satisfactory 
anatomic cure rates (between 79 and 86%), few serious complications (3.4%) and 
exposures in 11%. Subjective improvements were seen in both questionnaire scores 
though not specifically for stress urinary incontinence. 
Among women undergoing the above prospective multicenter cohort study, sexually 
active women were separately analyzed with regard to sexual function before and one 
year after surgery using a specific questionnaire.  Overall symptom scores deteriorated 
at one year after surgery irrespective of the surgically corrected compartment and of 
anatomical corrective success. The deterioration was attributed primarily to behavioral-
emotive and partner related items and not specifically to dyspareunia. 
To determine the histological inflammatory response to large vaginal mesh, a 
histological study was performed. Ten women undergoing prolapse surgery using mesh 
from the prospective cohort study above underwent vaginal punch biopsy sampling 
prior to surgery and one year after. The specimens were analyzed microscopically 
regarding inflammatory response and compared to 8 healthy controls. At one year, a 
persisting low grade host-implant reaction was seen in patients. 
Data from the above prospective cohort study was combined with data from a 
randomized controlled study comparing transvaginal mesh surgery for anterior prolapse 
with traditional plication techniques. Only women undergoing anterior repair with 
mesh were analyzed and potential risk factors for developing exposures were assessed. 
We found that women who smoked, had given birth to more than two children and who 
had systemic inflammatory disease had greater odds of developing exposures. 
In conclusion, the four studies in this thesis have shown that transvaginal mesh for 
pelvic organ prolapse provides satisfactory anatomical and subjective cure rates at one 
year with relatively few serious adverse events. However there are significant risks of 
deteriorated sexual function (especially in behavioral/emotive and partner related 
aspects), vaginal non infectious inflammation and mesh exposures. We have shown that 
women who smoke, have more than two children and suffer from somatic 
inflammatory disease are at greater risk of mesh exposures. In spite of partly 
encouraging results, the findings pose significant challenges to the overall success and 
acceptance of the procedure. Prior to recommending the use of mesh for pelvic floor 
correction, all available information on symptoms, the nature of the prolapse, surgical 
short and longterm outcomes as well as potential risks and benefits must be adequately 
analyzed and considered. 
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1 INTRODUCTION 
Pelvic organ prolapse is reported in up to 50% of parous women,(1) with a reported 
lifetime risk of undergoing pelvic reconstructive surgery around 11%.(2) However, 
after traditional prolapse surgery recurrence rates up to 58%,(3) have been reported. 
Inspired by success in mesh assisted sling procedures for stress urinary incontinence, a 
rapid and widespread transition from traditional pelvic organ prolapse surgery to 
surgical techniques using biomaterials has transpired, the aim of which is to improve 
the durability and tensile strength of anatomic restoration and to improve on the often 
unsatisfactory surgical outcomes after prolapse corrective surgery.(4)  
The unique vaginal microenvironment, dynamics, biochemical exchange and 
immunological response to some extent prevents the generalisability of results from 
animal studies, or other areas of biomaterial use, such as inguinal hernia surgery to the 
pelvic floor.(5) When used for the tension-free vaginal tape (TVT) procedure, 
macroporous, monofilament, polypropylene mesh has shown advantageous properties 
as compared with other synthetic biomaterials.(6, 7) As a result, polypropylene mesh 
has become the most commonly marketed biomaterial for use in and pelvic organ 
prolapse surgery.  
It has been suggested that in order for biomaterials to provide the intended pelvic 
floor support, they need to be “anchored” outside the afflicted tissues.(8) This has given 
rise to trocar-guided transvaginal surgical techniques using a transobturator or 
transgluteal approach, passing mesh fixation arms through the arcus tendineus fascia 
pelvis or the sacrospinous ligaments.(8) Studies on perioperative morbidity and short-
term clinical outcomes using trocar-guided mesh kits have yielded promising objective 
and subjective clinical outcomes.(9-12)  
Increasing the surface size and adding points of fixation may alter the biomechanical 
characteristics of the mesh. The introduction of larger mesh may also change the 
histological and inflammatory response of the vaginal tissues to the implant as 
compared to the small sized tapes used for stress urinary incontinence surgery. Many 
important long term outcome measures have not yet been accounted for and mesh 
related complications are a significant cause of morbidity. Adverse mesh reactions such 
as exposure, infection, pain and sexual dysfunction are of major concern in relation to 
the use of foreign body materials for pelvic reconstructive surgery.(13) The favorable 
outcomes associated with the use of polypropylene mesh for the TVT procedure cannot 
be assumed valid also for other areas of pelvic surgery. Due to the lack of clinical 
safety and efficacy data use of polypropylene mesh for pelvic organ prolapse surgery 
remains a source of controversy and further clinical research has been called for.(13-15) 
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2 BACKGROUND 
2.1 ANATOMY 
2.1.1 Embryology of the urogenital system 
Although genetic sex is predetermined at fertilization the gender is not apparent until 
the 7th week of embryonic life and is dependent on the testis-determining factor (TDF), 
encoded on the Y chromosome. The basic developmental path is female, not requiring 
estrogen but rather the absence of testosterone. The urinary and genital systems develop 
from the mesodermal layer and are closely related. In the 5th week, the cloaca is formed 
from a mesodermal fold. It is then divided by the urorectal septum into the posterior 
anorectal canal and the anterior urogenital sinus from which the bladder and urethra 
form.  
The ovaries originate from germ cells proliferating in the genital ridges at the 6th 
week, to where they have migrated from the wall of the yolk sac. Initially there are two 
pairs of genital ducts; the mesonephric ducts from which the ductus deferens, 
epididymis and the seminal vesicle form in the male, and the partially fused Müllerian 
or paramesonephric ducts from which the uterovaginal canal and fallopian tubes, as 
well as broad ligament form in the female. During the 7th developmental week, 
hormones initiate the domination of one duct. The distal fusion of the paramesonephric 
ducts occurs at the anterior urogenital sinus in the 8th to 11th week and bring together 
folds of the peritoneum creating the broad ligament and dividing the pelvic cavity into 
the posterior rectouterine and anterior vesicouterine pouch.(16, 17) 
 
2.1.2 The female pelvic floor organs 
2.1.2.1 The bony pelvis 
The female pelvic floor organs are enclosed in the skeleton of the pelvis which is made 
up of the sacrum and coccyx, and the paired hip bones (os coxae) which fuse anteriorly 
at the symphysis pubis. Important landmarks on the hip bones are the ischial spine 
which is the point of fixation for the sacrospinous ligament, and the obturator foramen 
covered on the inside with the obturator muscle and through which obturator nerves 
and vessels are transmitted cranially. 
 
2.1.2.2 The vagina and its support 
The vagina is a hollow and elastic cylinder extending from the vulvar vestibule to the 
uterus and is suspended most cranially to the paracolpium (endopelvic fascia 
surrounding the cervix). DeLancey described three levels of vaginal support where the 
most cranial attachments are named Level I. In the mid portion, Level II, the vagina is 
attached ventrally and laterally to the thickened endopelvic fascia and the tendineus 
arch and levator via the arcus tendineus fascia pelvis. Lateral detachments of the vagina 
can be seen in some anterior prolapse and cystocele formation. In the distal portion, 
Level III, the vagina is fused to the medial surface of the levator ani muscles, urethra, 
and perineal body. The vagina’s axis is almost horizontal in the upright position, and 
lies ventral to the lower rectum and anal canal, and posterior to the bladder and urethra. 
The fibromuscular vaginal wall incorporates anteriorly the pubocervical and posteriorly 
the rectovaginal fascias which consist of condensations of connective tissue and smooth 
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muscle rather than fibrous tissue as the name would suggest. The perineal body is the 
hub or center of the superficial part of the pelvic floor, connecting the perineal 
membrane, the transverse superficial perineal muscle, bulbocavernous muscle and 
pubovisceral muscle as well as the anal sphincter and posterior vaginal wall. 
 
Figure 1. Levels of vaginal support as described by DeLancey 
 
 
Reprinted with permission from the author. 
 
2.1.2.3 The bladder and urethra 
The bladder is a spherical organ whose base, or trigonal area, lies ventrally to the 
anterior vagina and whose lateral sides are confined by the levator ani and internal 
obturator muscle. The trigone is involved in the regulation of continence and has 
primarily sympathetic innervation. The internal urethral orifice forms the third corner 
of the trigone (together with the two ureteral orifices) and the urethra then extends, 
surrounded by endopelvic fascia, 3-4 cm to the vulvar vestibule anterior to the vagina. 
Inner longitudinal and circular smooth muscle fibers are found along the urethra, as 
well as, circular skeletal muscle fibers most densely found in the midurethral segment 
forming the sphincter urethrae. The urethral sphincter provides resting muscle tone and 
passive continence. Voluntary or reflex continence, however, is provided by 
contraction of the puborectalis muscle as a response to suddenly raised intra-abdominal 
pressure. These basic principles of urinary continence do, however, remain 
incompletely understood and other intricate mechanisms such as tensile support of the 
urethra may also be involved in the maintenance of continence. 
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2.1.2.4 The muscles and ligaments of the pelvic floor 
The muscles of the proper pelvic floor form a broad trampoline like suspension of the 
intra-abdominal cavity with perforations for the rectum, vagina and urethra. It is made 
up of the levator ani (incorporating the pubovaginalis, puborectalis, and iliococcygeus 
muscels), and is attached at the sides to the tendineus arch. The tendineus arch (or arcus 
tendineus) is often described as a densification of the fascia covering the obturator 
muscle on the inside of the obturator foramen extending from the pubis to the ischial 
spine, stretching from the pubis anteriorly to the coccyx posteriorly. During contraction 
the horse shoe shaped tendineus arch compresses the rectum, vagina and urethra 
towards the pubis. 
The arcus tendineus fascia pelvis is a caudal section of the tendineus arch providing 
attachment for the vagina laterally and ventrally. The cardinal ligaments attach to the 
sides of the cervix and extend laterally, the sacrouterine ligaments attach circularly 
round the cervix and extend bilaterally to the sacrum and both cardinal and 
sacrospinous ligaments fixate the uterus in place. The pubourethral and pubovesical 
ligaments attach to the urethra/bladder and extend to the pubis fixating these organs. 
 
2.1.2.5 The endopelvic fascia 
The endopelvic fascia is a supportive fascial structure surrounding the organs and 
structures in the pelvic floor, providing attachment between them, in certain places 
becoming dense (sacrouterine ligaments) and in others membranous (urogenital 
diaphragm). It is largely made up of smooth muscle and is therefore flexible and not 
passively rigid. 
 
2.1.3 Normal vaginal histology 
A mucous membrane is a functional unit lining cavities which connect with the outside 
of the body. The human vaginal wall consists of a mucous membrane, a muscular layer 
(muscularis mucosae) and an outer adventitia. The mucous membrane or mucosa 
consists of an outer layer of stratified squamous epithelium measuring 150 to 200 μm in 
thickness and an underlying supportive connective tissue layer (lamina propria) whose 
papillae project into the undersurface of the epithelium. The basal lamina or basement 
layer separates the epithelium from the underlying lamina propria. The squamous 
epithelium is generally not keratinized and therefore nuclei can be seen in epithelial 
cells throughout the thickness of the epithelium. Growth and accumulation of glycogen 
in the epithelium is stimulated by estrogens and the continuous desquamation of the 
most superficial cells allows their analysis in vaginal smears. 
In the dense outer region of the connective tissue layer or lamina propria, abundant 
elastic fibers and collagen are found, allowing for stretch and expansion in conjunction 
with childbirth. Fibroblasts are found scattered in the connective tissue where they are 
responsible for the synthesis of collagen and elastic fibers. In the deeper and less dense 
‘submucosal’ region abundant blood vessels are found. Inflammatory cells such as 
lymphocytes and leukocytes are spread out in the connective tissue.(18) The muscularis 
mucosa consists of smooth muscle in an inner circular and an outer thicker longitudinal 
layer and the adventitia which is the deepest part consists of dense connective tissue 
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and an outer looser layer which connects with the adventitiae of surrounding structures, 
becoming part of the endopelvic fascia. 
 
2.2 PELVIC ORGAN PROLAPSE 
Pelvic organ prolapse is a benign condition where the vaginal walls descend, bulge and 
eventually protrude out of the vagina. The ICS definition stipulates pelvic organ 
prolapse involves: “The descent of one or more of: the anterior vaginal wall, the 
posterior vaginal wall, and the apex of the vagina (cervix/uterus) or vault (cuff) after 
hysterectomy.” 
 
2.2.1 Epidemiology 
Pelvic organ prolapse is a common disorder reflected by the large number of 
reconstructive procedures performed yearly. More than 300,000 prolapse procedures 
were performed in the United States in 2003, a number that has increased from just 
over 225,000 in 1997.(19, 20) In Sweden the corresponding figure for 2010 was almost 
8,700 procedures (www.socialstyrelsen.se/statistik). The peak incidence of pelvic organ 
prolapse surgery occurs in the age group 60-69 years (41.1 per 10 000 women),(21) and 
the number of parous women who present with pelvic organ prolapse to some extent 
reaches 50% in some populations.(1) The number of women who report symptomatic 
pelvic organ prolapse may, however, be as low as 8.3%.(22) These figures indicate that 
loss of pelvic organ support is present in most women after childbirth and may be 
considered normal. However, there is no universal consensus on when descensus of the 
vagina signifies abnormality or dysfunction and motivates intervention.  
Approximately 11% of women in industrialized societies undergo surgery for pelvic 
organ prolapse or urinary incontinence,(2, 23) and after surgery as many as 41-58% 
have recurrent prolapse. As a consequence 10-29% of women undergo reoperation or 
secondary procedures.(2, 3, 24) The most common operation for pelvic organ prolapse 
is the anterior repair. Olsen et al.,(2) found that 40.1% were operated in the anterior 
compartment only, 7.3% in the posterior compartment only, and 5.7% in the apex only. 
These figures are reflected by the Women’s Health Initiative where cystocele was 
found in 34% and rectocele in 19% of the participants at clinical examination.(25) 
 
2.2.2 Pathophysiology and Etiology 
The different types of prolapse include anterior wall prolapse (cystocele, urethrocele, 
and paravaginal defects), posterior wall prolapse (enterocele, rectocele, perineal 
deficiency) and upper vaginal prolapse (uterine prolapse or vaginal vault prolapse after 
hysterectomy), or a combination thereof. The etiology of pelvic organ prolapse is 
intricate and not fully understood. Risk factors include vaginal delivery, instrumental 
delivery, multiparity,(21, 26) raised intra-abdominal pressure (e.g. caused by coughing, 
straining, overweight),(27) congenital or acquired connective tissue abnormalities,(28) 
ageing and menopause.(29) It has also been shown that genetic predisposition,(30) and 
hysterectomy,(31) contribute to the development of prolapse. Based on these reports it 
is biologically plausible that pelvic organ prolapse has a complex and multifactorial 
etiology.  
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2.2.3 Symptoms 
Women with prolapse may present a variety of symptoms caused either by the 
descensus of the pelvic organ themselves or indirectly by the effects of loss of support 
on the pelvic organs. Pelvic heaviness, vaginal bulging or protrusion, a vaginal globus 
sensation, lower urinary tract symptoms, bowel emptying difficulties, and sexual 
dysfunction are common symptoms among women with pelvic organ prolapse.(32, 33) 
Several symptoms often coexist but aside from vaginal bulging it remains uncertain 
which symptoms are specific to prolapse.(34) Co-existing urinary incontinence is a 
particularly common complaint affecting up to 44% of women with pelvic organ 
prolapse.(35) Incontinence procedures are sometimes performed concurrently with 
prolapse surgery but the practice is a source of controversy.(36, 37) Other lower urinary 
tract symptoms frequently associated with pelvic organ prolapse includes a weak 
urinary stream, urinary retention, and urinary urgency.  
 
2.2.4 Clinical evaluation of prolapse 
Diagnosing pelvic organ prolapse in most cases involves a clinical examination which 
describes vaginal anatomy and topography. In cases with complex clinical findings 
radiographic assessments such as defecography or MRI may be warranted.(38, 39) 
Attempts have been made to achieve a global standard description of pelvic organ 
prolapse but none have been widely accepted until 1996 when the ICS standardization 
committee introduced the Pelvic Organ Prolapse Quantification system (POP-Q).(40) 
Previous systems like Porges, Baden-Walker and Beecham are still in use but the POP-
Q is currently considered gold standard. (41) 
According to the POP-Q, absence of prolapse is defined as stage 0 support on a scale 
from 0-IV.(42) The position is determined at maximum strain or Valsalva with the 
patient in a lithotomy position. The hymen is the fixed point of reference defined as 
point zero (or the zero plane), and the anatomic position of six defined points are 
measured in centimeters above (negative numbers) or below (positive numbers) the 
hymen plane. Another three measurements are performed to complete the POP-Q 
system describing the genital hiatus, the perineum and vaginal length.  
Since it is often uncertain which specific organ lies behind the protruding vaginal 
wall, it is recommended that the prolapse be described according to its pelvic 
compartment rather than the presumed underlying organ (i.e. anterior wall prolapse 
instead of cystocele, posterior wall prolapse rather than rectocele). The total of 9 points 
and landmark measurements included in the POP-Q system are described in Table 1 
and Figure 2 below.  
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Table 1. Landmarks used in POP-Q 
Aa: Point 3cm 
proximal to ext 
urethral meatus. 
Possible values: 
-3cm to +3cm 
Ba: Point representing 
most distal position of 
anterior vaginal wall. 
 
C: Point representing 
most distal edge of 
cervix/vaginal cuff. 
gh: Distance from 
middle of ext urethral 
meatus to posterior 
midline hymen (cm). 
pb: Distance posterior 
margin of gh to the 
midanal opening (cm). 
tvl: Greatest depth of the 
vagina when C/D reduced 
to normal position (cm). 
Ap: Point 3cm 
proximal to the hymen. 
Possible values: 
-3cm to +3cm 
Bp: Point representing 
most distal position of 
posterior vaginal wall. 
 
D: Point representing 
posterior fornix/Douglas. 
(Omitted if patient does 
not have cervix) 
 
 
 
 
Figure 2. POP-Q measurements 
 
Stages of prolapse are assigned after the quantitative description, as seen in Table 2.  
 
  
D
Aa
Ap
Ba
Bp
gh pb
C
  
Table 2. P
Stage 0  
Stage I  
Stage II  
Stage III  
Stage IV  
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2.3.2 Conservative and mechanical methods 
Conservative methods of treatment for pelvic floor disorders include pelvic floor 
muscle training (PFMT), electric stimulation, biofeedback, lifestyle interventions such 
as weight loss, reducing exacerbating activities (e.g. coughing and lifting) and treating 
constipation. It is not completely understood how (or if) these methods are valid in the 
management of prolapse. There are some encouraging results regarding PFMT for 
symptomatic pelvic organ prolapse,(46) but the evidence is inconclusive. Mechanical 
devices such as pessaries lift the bulging vaginal walls when lodged between the 
posterior fornix and the pubis. Most often pessaries are made from plastic or rubber 
mixes, subsequently they are cheap, but in general pessaries are used in women with 
milder prolapse, in those who are planning future pregnancies, women waiting for 
surgery or patients who are unsuitable for surgery.(47) 
 
2.3.3 Traditional Surgical techniques 
Surgery is the mainstay for the treatment of pelvic organ prolapse. It has long been 
believed that surgical repair in one vaginal compartment predisposes a patient to 
prolapse in others. Consequently, a tradition evolved were pelvic surgeons addressed 
several potential defects at the same time, hence the historical popularity of the 
complete Manchester technique. In later years, however, there has been a shift towards 
operating only the affected compartment and leaving future repair until the need 
arises.(48) Surgical strategies involve either obliterative (used primarily in elderly 
women with no wish for sexual activity) and reconstructive techniques.  
Reconstructive procedures can be performed by an abdominal, laparoscopic or 
vaginal approach and may include removal of the uterus (hysterectomy).(49) As 
compared to the abdominal route, the vaginal route for reconstructive procedures has 
become increasingly popular since it can be performed in regional or local anesthesia, 
has low complication rates, and is comparatively cheap.  
 
2.3.3.1 Manchester/Fothergill operation 
Originally developed in Manchester 1908 where many hard laboring women in the 
fabric industry developed pelvic organ prolapse, Donald originally described the 
technique in 1888. It was subsequently modified by Fothergill and involved dissection 
of the bladder, amputation of the cervix, suturing of the cardinal ligaments to the 
anterior cervical stump and closure of the posterior vagina over the opening. A so 
called ‘complete’ Manchester operation also included an anterior and posterior 
colporraphy.(17) This operative technique has been used over the past 100 years 
without much change and for almost all types of prolapse. 
 
2.3.3.2 Anterior colporraphy 
(Greek: Kolpos - fold or hollow, Raphe - a seam on an organ) 
 
Howard Kelly described the anterior colporraphy in 1914 originally as an operation for 
stress urinary incontinence.(50) It was designed to improve urethral support by 
periurethral plication sutures. The abdominal Burch colpossuspension, developed in 
1961 which involves attachment of the periurethral fascia at the level of the bladder 
neck to the iliopectineal ligament (Cooper’s ligament) has the same objective.(51) 
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Since then, however, tension free tape procedures have become gold standard in stress 
urinary incontinence surgery. The anterior colporraphy remains in use but primarily for 
repair of anterior vaginal wall prolapse.  
Anterior colporraphy involves a transvaginal incision of the anterior vaginal wall 
and dissecting the bulging bladder off the cervix. The bladder is pushed cranially (and 
sometimes invaginated with a purse string suture) and the pubocervical fascia is 
adapted in the midline after which the vaginal epithelium is closed. Sometimes excess 
vaginal mucosa is removed. If defects in the fascia are identified, site specific repair 
can be performed (specific suturing of identified defects) and if lateral detachments are 
identified, lateral defect repair can be performed where the endopelvic fascia is 
reattached to the arcus tendineous fascia pelvis. This procedure is comparatively 
intricate compared to anterior colporraphy and associated with increased morbidity and 
poorer results compared to lateral repair using the abdominal route.(52) 
 
2.3.3.3 Posterior colporraphy 
The most commonly used procedure for posterior wall prolapse was described by 
Francis and Jeffcoate.(53) At posterior colporraphy the posterior vaginal wall is incised, 
the distal rectum freed from the pararectal/rectovaginal fascia after which the levator 
ani muscles are plicated over the rectum in the midline and the vaginal mucosa is 
closed. Prolapse in the upper segment of the posterior wall is often caused by an 
enterocele whereas a lower segment prolapse often is caused by a rectocele.(39) The 
distinction between the two can be clinically challenging and often diagnosed in the 
operating room. Surgical repair of an enterocele involves opening the peritoneum and 
placing a purse string suture in the parietal peritoneal tissue to obliterate the peritoneal 
cul de sac. The defect is then supported with a McCall culdoplasty by suturing the 
sacrouterine ligaments into the midline and finally the vaginal epithelium closed. This 
operation can also be performed by the abdominal route ad modum Moschowitz.(54) 
Similarly to suturing site specific defects in the anterior pubocervical fascia, site 
specific repair can also be performed in the rectovaginal fascia.(55) 
 
2.3.3.4 Perineoraphy 
The perineal body is often shortened as a result of obstetrical laceration and may be 
present in patients with posterior wall prolapse. Perineal reconstruction is therefore 
often a part of posterior vaginal wall repair. This is usually performed with a simple 
suturing technique. 
 
2.3.3.5 Colpocleisis 
A total or partial (le Fort’s) is an obliterative technique whereby the vagina is totally or 
partially closed off by deepithelialising the anterior and posterior vaginal surface and 
then adapting and suturing the surfaces together. The procedure is rarely performed 
today.  
 
2.3.3.6 Colpopexy 
In cases of vaginal vault prolapse, sacral colpopexy is often the method of choice. This 
procedure is performed using either the abdominal route where the vaginal apex is 
lifted cranially and attached to the sacral promontory (sacrocolpopexy) or using the 
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vaginal route suturing the apex to the sacrospinous ligament (sacrospinous fixation). 
Attachment to the sacral promontory is performed by open or laparoscopic approach. 
Although associated with an increased morbidity when compared to sacrospinous 
fixation, sacrocolpopexy involves transpositioning a mesh between the vaginal apex 
and the sacral promontory and provides satisfactory anatomical long-term results.(56) 
In addition, less commonly used techniques for recreating level I support includes 
fixation to the iliococcygeus and uterosacral ligaments. The McCall culdoplasty 
involves suturing uterosacral and cardinal ligaments to the vaginal cuff at the time of 
hysterectomy or posterior colporraphy.(57) 
  
2.3.4 Outcomes of traditional prolapse surgery 
The anatomical outcome after surgery has long been considered a straightforward and 
objective measure by which surgical success is determined. Recently it has, however, 
become increasingly apparent that vaginal topography postoperatively does not 
adequately correlate to persistent prolapse symptoms or quality of life.(58) It has 
therefore been suggested that compound measures which include anatomical results, as 
well as, subjective symptom scores should be used to describe surgical outcomes in 
pelvic organ prolapse surgery.(58) There is also an inherent problem in comparing 
outcomes between different procedures because of the multitude of different surgical 
techniques in use, the lack of standardization of procedures, concomitant procedures 
performed at the time of prolapse repair, and the diverse subjective outcome measures. 
The definitions of success and failures vary between studies although recently many 
investigators have used POP-Q stage 0 and I to define postoperative success and stage 
II or more as failures. Anatomical results for traditional techniques, especially anterior 
repair, show up to 50% anatomical failures in some reports.(24, 59) Choosing the 
wrong procedure due to misdiagnosis of the prolapse may of course affect outcomes 
negatively, for example not addressing an apical defect at the time of anterior vaginal 
wall prolapse (cystocele) repair. For posterior prolapse, the anatomic success rates are 
higher than for anterior repair (80-90%) and the midline plication technique has shown 
superior results as compared to site-specific repair or transanal approach.(60) 
In general, vaginal prolapse procedures are associated with low complication rates 
and are often performed in day surgical settings in regional or even local anesthesia. 
Major perioperative complications are uncommon but pelvic organ injury, bleeding and 
hematomas may occur. Minor post operative complications include urinary retention 
and urinary tract infections (Table 4). Late complications such as de novo stress urinary 
incontinence have been noted in up to 15% of all prolapse operations.(52) Dyspareunia 
after posterior repair is a known complication primarily when levator ani plication is 
performed,(61, 62) and has resulted in a shift towards simple fascial plication.  
 
2.4 IMPLANTS AND MESH 
The unsatisfactory recurrence rates associated with traditional pelvic organ prolapse 
repair have led to the introduction of implants (grafts or mesh) to provide weak or 
damaged tissues with tensile strength and mechanical support. The introduction of 
mesh in inguinal hernia surgery has lowered recurrence rates by 50% and mesh 
augmentation has evolved into the standard care for inguinal herniorraphy.(63) The 
ambition to identify the ideal graft for urogynecological surgery is a paramount yet 
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intricate goal, not only in terms of biological tolerance but also in practical and 
economic aspects.  
 
2.4.1 History 
The use of implants in vaginal surgery traces back to the early 20th century when F.H. 
William in 1904 introduced an operation for the reduction of uterine prolapse by using 
kangaroo tendon as a purse-string through both broad ligaments. Human fascia lata 
transplants were used for the treatment of genital prolapse in 1914 and in 1938 fascia 
lata from ox was used for reconstruction of the round ligaments.(43) In 1941 ribbon 
catgut was used for suspension of uterine prolapse. Aldridge introduced the fascial 
sling for urethral support in 1942, and in the same year homologous fascia lata was 
used for vaginal surgery. Permanent suture materials was first used in 1959 and in 1964 
Ferguson was the first to introduce Marlex mesh.(43) Numerous biomaterials have 
been used since then, mainly for incontinence surgery and vaginal vault suspension. 
 
2.4.2 Implant subgroups 
The ideal properties of mesh includes a lack of a foreign body reaction, integration with 
the host tissues, persistent mechanical properties and long term support to the target 
tissues. In addition it needs to be chemically inert, non-carcinogenic, non-allergenic, 
and easily manufactured in sterile and affordable conditions. Host-vs.-implant reactions 
are influenced by the mesh pore size since it must allow for the invasion of fibroblasts 
and blood vessels for incorporation and integration with host tissue, as well as, 
permitting macrophages (10-20 μm in diameter) to pass in order not to compromise 
antimicrobial defenses. Synthetic meshes are categorized into four subgroups (type I-
IV) according to the weave and interstitial pore size,(64) as in Table 3. 
 
Table 3. Classification of synthetic mesh. 
Absorbable Polyglactin 910 (Vicryl)   
  Polyglycolic acid    
Permanent Monofilament (macroporous 
>75μm pores) 
Type I     polypropylene, 
polyvinylidene, fuoride  
Marlex  
Prolene 
TVT  
Monarc  
Gynemesh  
Trelex 
  Multifilament (macro and 
microporous with    <10μm 
pores) 
Type II  
Microporous Polytetra-
fluoroethylene 
GoreTex 
   Type III      Macroporous Teflon  
Mersilene  
Dacron  
IVS 
  Submicronic pore size (<1μm) Type IV 
Silicone, silicone-coated 
Rarely used in gyne-
cological surgery 
Mixed e.g., Absorbable + non 
absorbable mesh 
Polypropylene + 
polyglactin 910= type III      
Vypro 
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Synthetic mesh has several potential advantages compared to biological grafts. They 
are readily available and do not require harvesting. Many synthetic compounds are 
versatile and can be produced with different weaves or knits and can be designed to 
have differing tensile strengths, elasticity, and weight properties. Absorbable meshes 
promote fibroblast activity and because of degradation (within 30-90 days) do not cause 
prolonged inflammatory reactions or infections. These beneficial traits of absorbables 
at the same time suggest a limited long term support. Mesh weight is considered to 
influence the immune response and light weight mesh is generally considered 
advantageous.(65) Mesh weights vary between light weight mixed mesh e.g. Vypro 
weighing 50g/m2 to 96g/m2 for plain polypropylene mesh such as Gynemesh. The pore 
size varies between different products from the 700μm Prolene mesh to the mixed mesh 
Vypro with pores of 2400μm.(8) The elastic limits and tensile strength of permanent 
synthetic mesh greatly exceed the biologically possible stress which may occur from 
raised abdominal pressure.(7) Thus, macroporosity of polypropylene monofilament 
mesh does not compromise the required durability and may contribute to the low rates 
of mesh complication when used for the tension-free vaginal tape procedure (TVT).(6)  
In both urogynecological surgery and abdominal hernia surgery, the use of and 
experimentation with mesh over many years has resulted in evidence supporting 
today’s preference of synthetic type I mesh over other mesh types. When used for the 
TVT procedure, macroporous, monofilament, polypropylene mesh has shown 
advantageous properties as compared with other synthetic biomaterials.(66) As a 
result, polypropylene mesh has become the most commonly marketed biomaterial 
also for use in pelvic organ prolapse surgery. Increasing the surface size and adding 
points of fixation may, however, alter the biomechanical characteristics of the mesh. 
The favourable outcomes associated with the use of polypropylene mesh for the TVT 
procedure can therefore not be assumed valid for other areas of pelvic surgery. Due to 
the lack of clinical safety and efficacy data, the adoption of polypropylene mesh for 
pelvic organ prolapse surgery remains a source of controversy.(13) 
 
2.4.3 Mesh surgical techniques 
The shape of mesh used to reinforce the prolapsed vaginal tissues is either self tailored 
to the required size with or without mesh arms, or determined by pre-fabricated mesh 
shapes from the manufacturer. In a further development of these implants it has been 
suggested that biomaterials need to be anchored in tissues outside the afflicted area to 
provide the intended pelvic floor support. This has given rise to standardized trocar 
guided mesh kits with extension arms extending from the central part of the mesh to 
either the arcus tendineus fascia pelvis (anterior compartment) or the sacrospinous 
ligaments (posterior compartment).  
The transvaginal mesh kit used in the present thesis (Prolift®, Gynecare, 
Somerville, NJ) was developed by French gynecologists and uses a polypropylene 
Type I mesh. The compartment specific surgical procedures have previously been 
described in detail,(8) but are outlined below.  The uniformly sized and shaped 
polypropylene mesh arms are passed through the arcus tendineus fascia pelvis using 
four metal trocars in the anterior vaginal compartment (Figure 4a). In the posterior 
compartment, the mesh is placed through a transgluteal approach, and the two 
extension arms are fixated to the sacrospinous ligament (Figure 4b).  
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2.4.4 Vaginal histopathology and immune response 
Use of biomaterials in humans results in a host-vs.-implant response caused by an 
activation of the innate immune system. This involves an activation of macrophages, 
phagocytes and complement factors. Later, and especially if microbes or proteins 
persist within the implant, the adaptive immune system also becomes activated causing 
a proliferation of lymphocytes. In chronic host-vs.-implant reactions, foreign body 
giant cells can be found. Assessments of the histopathologic response to implants is an  
important step in recognizing potential detrimental inflammatory reactions and in vivo 
mesh tolerance.(6) It is likely that larger mesh induces a greater immune response than 
small mesh used for incontinence surgery and data from the latter cannot be 
extrapolated to the former.(65) 
 
2.4.5 Success rates and complications of surgical implants 
The International Urogynecological Association (IUGA) and ICS have recently 
published a report on the terminology and classification of mesh related complications 
in female pelvic floor surgery. The aim is to allow future data comparisons and a 
possible application is to provide a basis for a registry.(67) It is recommended that 
terms with greater physical specificity and clarity be used, for example the generic term 
“erosion” should be avoided and the term exposure used instead. The system classifies 
exposures and other complications according to category, time and site with 
explanations or subclassifications regarding general description, patient symptoms and 
infections. 
Similar to traditional surgery there are a wide variety of mesh procedures described 
for pelvic organ prolapse repair and patients often undergo concomitant procedures, 
making comparisons and definitive conclusions difficult. Case series and prospective 
cohort studies greatly outnumber randomized trials in the literature.(52) Follow-up 
times are limited to 1-3 years postoperatively and although systematic reviews show 
improved anatomical outcomes when using synthetic mesh for anterior repair as 
compared to traditional surgery, longer follow-up and multiple center data is 
needed.(68) Observational studies using the Prolift® mesh kit show anatomical success 
rates ranging from 92-99%, visceral injury in 1-6.6%, de novo SUI in 4.8–24.3% and 
mesh exposure rates ranging from 2–12%.(69) These figures are similar to recent 
randomized controlled studies showing higher success rates for mesh as compared to 
traditional methods.  
 
2.4.5.1 Exposures 
Mesh exposures are of major concern in mesh surgery as illustrated by the FDA’s 
notifications in 2008 and 2011.(70) Exposures can occur at any time after surgery but 
are usually seen within the first year,(71) when the vaginal mucosa covering the mesh 
becomes thinned eventually exposing the mesh. This may result in vaginal discharge, 
bleeding, pain and discomfort. Exposures usually arise in the vaginal walls but can also 
be seen in the bladder or rectum and are visualized on vaginal examination, cystoscopy 
or rectosigmoidoscopy. Suggested risk factors are concomitant hysterectomy, smoking, 
increased BMI and age, as well as, an inverted T-incision or proximity to the vaginal 
scar.(71-74) Minor exposures often heal after local antibiotic or estrogen treatment, 
whereas larger exposures may need partial or total mesh excision and in rare cases 
extensive repeated surgery. 
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Figure 5. Mesh exposure after posterior mesh repair. 
 
 
 
2.4.5.2 Lower urinary tract dysfunction 
Iatrogenic elevation and straightening of the urethra during pelvic organ prolapse 
surgery is thought to negatively affect urethral closing pressure and increase the risk of 
de novo SUI. It is a common notion that the use of mesh increases this effect and the 
risk of de novo SUI may be greater for mesh than for traditional repair.(75-77) For 
obstructive urinary tract symptoms anterior repair with mesh have relieved 
symptoms,(78) whereas others have shown increased detrusor overactivity after the use 
of mesh.(79) 
 
2.4.5.3 Sexual dysfunction and pain. 
A major concern associated with the use of synthetic non absorbable mesh for 
reconstructive pelvic floor surgery is the risk for adverse effects on sexual function 
including dyspareunia. De Tayrac observed a 13% rate of de novo dyspareunia after the 
use of mesh for prolapse repair, although some patients in this study actually reported 
an improved sexual function.(80) Studies using absorbable mesh or grafts suggest that 
postoperative dyspareunia is less common,(81) although concerns for unsatisfying 
durability of degradable implants have demoted their use in prolapse surgery. Evidence 
regarding dyspareunia in traditional prolapse surgery is conflicting, with some trials 
showing improvements,(82) whereas traditional posterior prolapse repair has shown 
dyspareunia in up to one third of patients.(61) 
After vaginal wall prolapse surgery postoperative dyspareunia may arise as a 
combination of disturbed nerve and blood supply to the vaginal wall impairing sexual 
arousal and lubrication. Overcorrection of the vaginal axis and tautness of the mesh 
may compromise vaginal elasticity, give rise to vaginal tension, and prevent swelling of 
the vagina at sexual arousal. The pain caused by tautness can also be experienced 
outside of sexual intercourse as focal tenderness especially over the mesh arms and is 
often considered to be the result of mesh contraction.(83) Sexual function is complex 
and comprises not only the physical ability to have intercourse but also psychological 
aspects like self esteem and self image, as well as, partner ability. The frequency of 
sexual dysfunction in women with urogynecological disorders is high and there is a 
paucity of data on how synthetic mesh for pelvic organ prolapse influences the various 
domains of female sexual function.(84) 
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Long term buttock, groin or pelvic pain can affect women after both traditional 
prolapse repairs, as well as, after mesh procedures with rates varying between 0-
18.3%.(85) Reasons for persistent pelvic pain may involve nerve damage, mesh 
tensions, and mesh contraction. 
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3 AIMS 
 
The aim of this thesis is to study clinical and histological aspects on the use of a trocar 
guided transvaginal mesh kit for pelvic organ prolapse repair. 
 
The specific aims were to: 
 
1. Investigate the subjective and objective clinical outcomes one year after pelvic 
organ prolapse repair using a trocar-guided mesh kit. (Paper I) 
 
2. Prospectively evaluate sexual outcomes one year after pelvic organ prolapse 
repair using a trocar-guided mesh kit. (Paper II) 
 
3. Examine the histological inflammatory response one year after transvaginal 
pelvic organ prolapse repair using mesh. (Paper III) 
 
4. Assess potential risk factors associated with the development of exposures 
one year after transvaginal pelvic organ prolapse repair using mesh.  
(Paper IV) 
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4 PATIENTS 
 
All patients included in the four studies attended one of the clinics taking part in the 
Nordic Transvaginal Mesh (TVM) group. The Nordic TVM group is an independent 
collaboration between clinicians in Sweden, Norway, Denmark and Finland with the 
aim of performing multicenter studies in pelvic reconstructive surgery. Patients 
included in paper I and II in the present thesis were included at 26 different clinics in 
the Nordic countries. The patients in paper III was a subgroup of patients only from the 
Department of Obstetrics and Gynecology at Danderyd Hospital. In paper IV data was 
combined from two multicenter trials including 52 clinics and limited to patients with 
anterior wall prolapse. All studies were approved by the Research Ethical Review 
Board in Stockholm and the appropriate IRB committees in all participating countries.  
 
4.1 PAPER I 
In this prospective cohort study 261 patients with symptomatic pelvic organ prolapse 
were included at 26 centers in the Nordic countries between June 2006 and March 2007 
(see Appendix 14.3 for participating centers). Nine women were excluded from the 
study due to missing information. Mean age at surgery was 66.3 (± 9.4 SD) years and 
median parity was 2 (range 0-7). Approximately half of the patients (50.8%) had 
undergone previous traditional prolapse surgery. Almost one tenth of the women were 
smokers (9.5%) and 88.9% were postmenopausal; 62.3% used local or systemic 
hormone replacement therapy. Almost half of the women underwent anterior repair 
(48.0%) whereas 27% underwent posterior repair and 25% anterior and posterior repair 
using either two separate meshes or a combined anterior-posterior mesh. 
 
4.2 PAPER II 
Sexually active women participating in a prospective cohort study between June 2006 
and March 2007 were included in this auxiliary study. A total of 105 women were 
included in 26 centers (see Appendix 14.3 for participating centers). Their mean age at 
surgery was 61.5 (±7.6 SD) years which was younger than the sexually inactive group 
(mean age 69.0 ±4.2 SD years). Median parity was 2 (range 1-6), mean BMI 26.8 (±4.3 
SD) kg/m2 and 89% were postmenopausal. 41% had undergone previous prolapse 
surgery. The proportion of women undergoing anterior prolapse repair was 44%, 
posterior 25% and combined anterior and posterior repair 31%. Aside from age, 
baseline characteristics were similar between the sexually active and inactive group.  
 
4.3 PAPER III 
Ten women with pelvic organ prolapse at the Department of Obstetrics and 
Gynecology at Danderyd Hospital were asked to undergo vaginal punch biopsy 
sampling. We also included 8 control subjects i.e. women undergoing vaginal surgery 
at the same clinic for reasons other than pelvic floor dysfunction. Exclusion criteria for 
patients and controls alike included pelvic organ cancer, severe rheumatic disease, 
systemic steroid treatment or connective tissue disorders.  
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4.3.1 Patients 
The mean age for the 10 patients was 67.1 (±7.5 SD) years, median parity was 2 (range 
1-4), and mean BMI was 26.5 (±4.8 SD) kg/m2. All of the patients were 
postmenopausal, 7 used local or systemic hormone replacement therapy and there were 
no smokers. 4 of the women underwent anterior prolapse repair, 2 posterior repair and 4 
combined anterior and posterior repair. 
 
4.3.2 Controls 
For the 8 controls mean age was 42 (±13.0 SD) years, median parity was 2 (range 0-2), 
two were postmenopausal and none used local or systemic hormone replacement 
therapy. Mean BMI was 23.6 (±4.0 SD) kg/m2 and none were smokers. 
 
4.4 PAPER IV 
In this study, all patients undergoing surgical repair of anterior vaginal wall prolapse 
with mesh in a prospective cohort study and a randomized controlled trial were 
included (see Appendix 14.3 for participating centers). Mean age at surgery was 65.3 (± 
9.6 SD) years, mean BMI was 26.5 (±3.8 SD) kg/m2 and median parity was 2 (range 0-
7). More than one third of the patients (35.6%) had undergone previous corrective 
prolapse surgery. There were 37 smokers (10.5%) and the number of women suffering 
from somatic inflammatory disease was 12 (3.4%) of which rheumatic disease was the 
predominant diagnosis. Most women (82.7%) were postmenopausal and 69.4% used 
local or systemic hormone replacement therapy. 
   23 
5 METHODS 
5.1 STUDY DESIGN 
In this segment the study design for papers I-IV included in the present thesis are 
outlined. 
  
5.1.1 Paper I 
A multicenter, prospective, cohort study evaluating subjective and objective clinical 
outcomes among women undergoing trocar guided transvaginal mesh surgery for 
pelvic organ prolapse. Clinical examinations and subjective symptom assessments were 
performed before surgery, at two months and one year postoperatively. Symptom 
assessments were performed using validated and condition specific questionnaires 
(described in section 6.3). Trial protocols were submitted to the clinical research unit 
at the Department of Obstetrics and Gynecology, Danderyd Hospital, Stockholm, 
Sweden, and only the principal investigators had access to the data. All gynecologists 
participating in the trial were experienced pelvic surgeons and had pretrial, 
supervised, hands-on training in operating room sessions. The transvaginal mesh 
manufacturing company had no influence over study aim, design, execution or 
analysis and interpretation of data.  
 
5.1.2 Paper II 
The focus of this study was to assess sexual function in women participating in a 
multicenter, prospective, cohort study. Clinical examination and symptom assessment 
using validated and condition specific sexual function questionnaires (section 6.3) were 
performed prior to surgery and one year after surgery. Only patients sexually active 
before surgery were included in the analysis.  
 
5.1.3 Paper III 
This was a prospective, comparative, histopathological study. Ten women included in 
the multicenter cohort study (see section 6.1.1.) from Danderyd Hospital were included, 
as well as, 8 control subjects. Vaginal punch biopsy sampling was performed at 
baseline and one year postoperatively in patients. In control subjects punch biopsies 
were obtained only at baseline. Mesh inflammatory response was investigated macro- 
and microscopically. 
 
5.1.4 Paper IV 
In this study we combined patients from two multicenter studies. Data on women 
having anterior trocar guided transvaginal mesh in a prospective cohort study and a 
randomized controlled trial were combined and analyzed to identify risk factors for 
clinical mesh complications. Both studies used the same surgical mesh kit for anterior 
prolapse repair (Gynecare Prolift® Anterior Pelvic Floor Repair System kit, Ethicon) 
and the study protocol was near identical for both studies with regard to inclusion and 
exclusion criteria, as well as pre- and postoperative care. The studies differed mainly by 
the randomized design in one study and that the prospective cohort study allowed 
concomitant surgery at the time of mesh kit repair. The present combined analysis of 
the two studies was limited to women who underwent anterior prolapse mesh kit repair 
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and did not include posterior or total mesh kit repair in the cohort study, or women 
having colporraphy (without mesh) in the randomized trial. 
 
5.2 CLINICAL EXAMINATION 
A clinical examination was performed at baseline, two months and one year. Objective 
outcome measures were anatomical prolapse stage and macroscopic signs of vaginal 
inflammation. POP-Q quantification was performed for prolapse staging and 
assessment of inflammatory status was performed using a macroscopic inflammatory 
scale.  
 
5.2.1 POP-Q 
Before undergoing pelvic organ prolapse surgery all patients underwent a 
gynecological examination in the supine position, using the POP-Q system. Methods, 
definitions, and descriptions conformed to the standards recommended by the 
ICS.(40) Postoperative prolapse stage 0–I was considered anatomical cure. POP-Q 
measurements and staging at pre- and postoperative examinations were recorded in a 
separate protocol.  
 
5.2.2 Macroscopic inflammatory scale  
At the time of designing the study, no internationally accepted standard terminology or 
classification system was available to assess vaginal epithelial inflammation after 
pelvic organ prolapse surgery. Therefore a scoring system devised by Zdichavsky was 
used.(86) The terminology in paper IV, and throughout this thesis, has been changed to 
reflect the recommended terminology but the classification system could not be 
implemented retrospectively. The terms “erosion” and “rejection” have been replaced 
by exposure and extrusion respectively. At vaginal examination, granuloma, (erosion) 
exposure, necrosis, infection and (rejection) extrusion were graded according to a 5 
point ordinal scale (0= none, 1= mild, 2= moderate, 3= pronounced, 4= severe). The 
scale is not formally validated for use in urogynecological surgery but has shown 
consistency with histopathologic assessments in a previous study assessing the use of 
biomaterials in pelvic floor surgery.(87)  
 
5.3 QUESTIONNAIRES 
In paper I and II subjective outcomes were measured using symptom specific 
questionnaires assessing the impact of pelvic organ prolapse on urinary symptoms, 
quality of life and sexual function.  
 
5.3.1 UDI-6 
The Urinary Distress Inventory (UDI) used in paper I was first developed in 1994 by 
Shumaker et al specific to symptoms associated with lower urinary tract dysfunction 
and genital prolapse.(88) The UDI focuses on lower urinary tract symptom distress and 
contains 19 items in its original form. The short form was developed and validated in 
1995,(89) and it is this form with 6 items that we used in the present studies. The UDI 
contains three subscales of lower urinary tract symptoms: Stress Symptoms, 
Obstructive/ Discomfort, and Irritative symptoms. There are two questions for each 
subscale in the short form. The item responses are assigned values of 0 for ‘not at all’, 1 
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for ‘slightly’, 2 for ‘moderately’, and 3 for ‘greatly’, hence the maximum score is 18. 
Scores are calculated in a simple additive fashion and for missing responses an average 
value is calculated and used, though if more than two responses are missing, the score 
should not be calculated. Higher scores indicate worse symptoms. 
 
5.3.2 IIQ-7 
The Incontinence Impact Questionnaire (IIQ) long and short forms were developed in 
parallel with the UDI. The 7-item short form used in the present studies is a quality of 
life impact assessment instrument and was constructed with a similar scoring system as 
the UDI. The IIQ is divided into 4 subscales; Physical Activity (2 items), Travel (2 
items), Social/Relationships (1 item), and Emotional Health (2 items). Scores are 
calculated in the same way as the UDI. The maximum score for the IIQ-7 is 21 and 
higher scores indicate worse quality of life. 
 
5.3.3 PISQ-12 
The long form of the Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire 
developed in 2001 is a 31-item questionnaire.(90) It was condensed into a 12-item short 
form and validated in 2003,(91) in order to achieve wider applicability in clinical and 
research settings. It assesses sexual function in women with pelvic organ prolapse or 
urinary incontinence and enables an evaluation of quality of life changes after surgical 
or medical interventions. Responses are graded on a 5-point ordinal Likert scale where 
0 is ‘never’, 1 is ‘seldom’, 2 is ‘sometimes’, 3 is ‘usually’ and 4 is ‘always’. The 
questionnaire is divided into 3 subscales: Behavioral/ Emotive (4 items), Physical (5 
items) and Partner Related (3 items). Scoring is performed in a simple additive fashion 
and the maximum score is 48. 
 
5.4 VAGINAL PUNCH BIOPSY SAMPLING 
Punch biopsy sampling in order to evaluate histological inflammatory response to 
vaginal mesh surgery was performed in paper III. Sampling was performed at the time 
of surgery in patients and controls but postoperative sampling at one year follow-up 
was only performed in patients. At the one year follow up patients received local 
anesthesia consisting of up to 5ml 0.25% Marcain® + epinephrine at the biopsy site. 
Biopsies were taken using a 6 mm wide and 10 mm deep punch biopsy instrument in 
the vaginal wall. The placing of the biopsy was in either the anterior or posterior 
vaginal wall in the same manner both pre- and postoperatively. By palpating the 
vaginal walls at the one year follow-up it was possible to feel the mesh beneath the 
mucosa and the biopsy was thereby taken in as close proximity as possible to the mesh-
tissue interface. For posterior biopsies the punch biopsy was directed diagonally 
downwards in order to avoid the rectum or diagonally upwards for anterior biopsies in 
order to avoid the urethra and bladder. Care was taken so as not to engage the mesh in 
the biopsy.  
 
5.5 HISTOLOGICAL ANALYSIS 
After sampling, biopsies were immediately immersed in a 4% neutral buffered 
formaldehyde solution after which they were transported to the pathology lab at Astra 
Zeneca R&D laboratories, Södertälje, Sweden, where they underwent dehydration and 
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embedding in paraffin. They were cut with a microtome into 5 μm sections and two 
specimens were prepared for each biopsy. The first was stained with hematoxylin and 
eosin and the other left unstained. The following parameters were evaluated using the 
stained specimens: 
• Total cell content in the subepithelial tissue 
• Epithelial thickness 
• Manual cell counts 
• Semiquantitative grading of inflammation, vasculitis and collagen density 
Using the unstained specimen the following was analyzed: 
• Elastin area fraction 
All measurements were performed together with a single pathologist blinded to 
clinical outcome. A computer assisted morphometric analysis was performed for total 
cell content and epithelial thickness measurements using a Sony® DXC-9100P 3-chip 
charge coupled device color camera mounted on an Axioplan™ 2 light microscope to 
capture images which were then analyzed using the MicroGOP 2000s image analysis 
software (Context Vision AB, Linköping, Sweden) installed in a SUN SPARCstation™ 
20 computer workstation.  
 
Figure 6. Axioplan™ 2 light microscope.       Figure 7. SUN SPARC work station. 
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Subepithelial total cell content 
The captured image was processed and an unbiased counting area frame of 50 000 μm2 
was superimposed on the image to calculate the numerical density of cells per μm2. 
Three such measurements were performed on each specimen. 
 
Epithelial thickness 
A binary epithelial profile of the images was created using the computer workstation 
and epithelial height (distance from basement layer to surface), distance from the top of 
the dermal papillae to the surface and distance between dermal papillae tops was 
measured.(92) 
 
Manual cell counts 
Using a light microscope and 100x oil immersion objective, specimens were examined 
and 200 cells counted; the cell counts for fibroblasts, macrophages, monocytes, 
granulocytes, lymphocytes, plasma cells and mast cells were registered. 
 
Semiquantitative grading 
Using the same microscope as above, overall inflammation and vasculitis was graded 
from 0 to 4 (0= none, 1= mild, 2= moderate, 3= pronounced, 4= severe) and collagen 
density graded as loose, fairly dense, moderately dense or very dense. 
 
Elastin area fraction 
Elastic fibers have autofluorescent properties; therefore they were analyzed using a 
Neofluor optical lens (Carl Zeiss, Jena, Germany) and fluorescent light in the same 
microscope, as above. Using the 40x objective, specimens were illuminated with 
ultraviolet light (filter range 450 to 500nm) to detect autofluorescence signals from the 
elastic fibers. A reference area of 54,162 μm2 was used for all captured images and 
each image consisted of 512 x 512 pixels. Area fraction was then analyzed using image 
analysis software as a percentage of the total tissue area; the measurement was 
performed three times for each specimen.(93) 
 
Figure 8. Neofluor optical lens (Carl Zeiss, Jena, Germany) with fluorescent light. 
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6 STATISTICAL ANALYSES 
All analyses were performed using Statistica (StatSoft, Inc., Tulsa, OK) and PASW 
(IBM, SPSS Inc; Chicago, IL, U.S.A) software and for all studies, p<0.05 was 
considered significant. 
 
6.1 PAPER I 
The IIQ-7 and UDI-6 questionnaire scores were calculated in a simple additive fashion 
(94). For dependent samples, comparisons on ordinal data between baseline and the 2-
month and 1-year assessment were performed using the nonparametric Wilcoxon 
signed rank test. A post hoc power analysis was performed based on the observed rates 
of anatomic cure (85%) and aiming at 80% power at a 95% confidence interval (i.e. 
β=20% and α=5%). A required total sample size of 196 was calculated which indicates 
that the number of patients in our study was adequate. 
 
6.2 PAPER II 
The summated PISQ-12 scores were calculated in a simple additive fashion where 
higher scores reflected better sexual functioning.(91) Comparisons between baseline, 2 
months and 1 year were performed for dependent samples using Wilcoxon signed rank 
test. The independent variables age, body mass index, current cigarette smoking, 
menopausal status, childbirths, anatomical failure, mesh exposures and concurrent 
surgery were tried in a forward multivariable logistic regression model in order to 
identify risk factors for a poor sexual function score. A post hoc power analysis aiming 
at 80% power at a 95% confidence interval (i.e. β=20% and α=5%) using a comparison 
of two observed means (mean PISQ score at baseline (15.5) and 1 year (11.7)) resulted 
in a sample size of 61 in each group. Preoperative scores could be calculated for 93 
patients and postoperative scores for 69 indicating an adequate sample size.   
 
6.3 PAPER III 
Comparisons of proportions were performed using the chi-square test. For data 
comparing baseline and one year, dependent samples were analyzed using the 
nonparametric Wilcoxon signed rank test. For independent samples comparisons were 
performed using the nonparametric Mann-Whitney U test. 
 
6.4 PAPER IV 
Comparisons on data between baseline and the two month and one year assessments 
were performed using the non-parametric Wilcoxon signed rank test for dependent 
samples, the Mann-Whitney U test for independent samples, and χ2 test for cross 
tabulation. Dichotomized variables assumed to be risk factors for the dependent 
variable (mesh exposure at one year) were chosen a priori clinical relevance and a 
literature review and analyzed using stratification and logistic regression. Multiple 
regression analysis was performed in both forward and backward stepwise removal of 
variables so as not to overlook any possible non significant variables in the univariate 
analysis. 
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7 RESULTS 
7.1 PAPER I 
7.1.1 Patient characteristics 
Of the 261 patients included at baseline, 9 were excluded due to missing information 
and 20 were lost to follow up. 243 (93%) and 232 (89%) attended the 2 month and one 
year follow-up respectively. For 128 patients (50.8%) mesh surgery was performed as a 
secondary procedure due to recurrent prolapse. Patient characteristics are shown in 
Table 5. 
 
7.1.2 Surgical characteristics 
Out of 261 patients, 121 (48%) underwent anterior repair, 68 (27%) posterior repair and 
63 (25%) underwent combined anterior-posterior repair. Concurrent surgery (usually 
posterior repair and perineorraphy in patients undergoing anterior repair) was 
performed in 34 (13%) patients. Serious perioperative complications occurred in 10 
(3.8%) patients: 8 bladder- and 1 rectal perforation and one hemorrhage in excess of 
1500 ml. Surgical characteristics are shown in Table 6. 
 
7.1.3 Anatomic outcomes 
Overall anatomic cure defined as POP-Q stage 0-I postoperatively was observed in 81-
87% of patients at 2 months and in 79-86% at one year depending on compartment. 
The highest cure rates were seen in the posterior compartment. Detailed cure rates, 
POP-Q stages and measurements are shown in Tables 7 and 8.  
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Table 5. Patient characteristics 
  
Anterior 
repair 
Posterior 
repair 
Anterior 
& Posterior  
  (n=121) (n=68) 
Repair 
 (n=63) 
Agea 66.0 ± 8.4 66.7 ± 10.2 66.3 ± 10.4 
Parityb 2 (0-5) 2 (0-6) 3 (0-7) 
Body Mass Indexa 27.1 ± 4.2 26.3 ± 4.1 26.1 ± 3.6 
Educational levelc    
Compulsory school 81 (67) 34 (50) 25 (40) 
High school 23 (19) 16 (24) 19 (30) 
College/university 15 (12) 13 (19) 12 (19) 
Annual incomec    
€ <10,000.0 22 (18) 12 (18) 10 (16) 
€ 10,000.0-30,000.0 77 (64) 25 (37) 24 (38) 
€ 30,000.0-40,000.0 5 (4) 12 (18) 5 (8) 
€ >40,000.0 2 (2) 4 (6) 1 (2) 
Smokerc    
Yes 9 (7) 9 (13) 6 (10) 
No 111 (92) 58 (85) 54 (86) 
Menopausalc    
Yes 110 (91) 59 (87) 55 (87) 
No 4 (3) 4 (6) 2 (3) 
Hormone Replacement 
Therapyc    
Local 49 (40) 22 (32) 21 (33) 
Systemic 33 (27) 19 (28) 13 (21) 
Somatic diseasesc    
CVD 52 (43) 26 (38) 34 (54) 
Thyroid dysfunction 16 (13) 8 (12) 8 (13) 
Asthma 9 (7) 6 (9) 5 (8) 
Arthrosis 6 (5) 6 (9) 4 (6) 
Diabetes 4 (3) 3 (4) 4 (6) 
Previous pelvic surgeryc    
Hysterectomy 55 (45) 37 (54) 39 (62) 
Prolapse 73 (60) 32 (47) 23 (37) 
Incontinence 8 (7) 9 (13) 6 (10) 
Salpingo-oophorectomy 27 (22) 22 (32) 10 (16) 
Other 9 (7) 8 (12) 3 (5) 
Numbers not adding up to 100% represent missing values. 
a Mean ± SD, b Median (range), c Number of patients (%) 
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Table 6. Surgical characteristics and adverse events associated with transvaginal mesh 
repair using the Prolift™ system 
  Anterior repair Posterior repair 
Anterior& 
posterior  
  n=121 n=68 repair n=63 
Operating time (min)* 59.7 ± 20.2 54.4 ± 18.6 96 ± 36.9 
Antibiotic prophylaxis‡ 116 (95.9) 66 (97.1) 60 (95.2) 
Bleeding (ml)* 103.4 ± 110.2 52.8 ± 55.6 168.5 ± 216.8 
Concurrent surgery    
Hysterectomy 3 (2.5) 0 (0) 5 (7.9) 
Anterior colporraphy NA 2 (2.9) NA 
Posterior colporraphy 8 (6.6) NA NA 
TVT/TVT-O 1 (0.8) 1 (1.5) 1 (1.6) 
Sacrospinous fixation 3 (2.5) 0 (0) 0 (0) 
Cervix amputation 1 (0.8) 0 (0) 0 (0) 
Perineoraphy 6 (5) 6 (8.8) 4 (6.3) 
Anesthesia‡    
Local  9 (7.4) 6 (8.8) 2 (3.2) 
Epidural 1 (0.8) 2 (2.9) 1 (1.6) 
Spinal 69 (57) 45(66.2) 38 (60.3) 
General 39 (32.2) 13 (19.1) 17 (27) 
Perioperative catheter‡ 105 (86.8) 55 (80.1) 58 (92.1) 
Postoperative vaginal tamponade‡ 89 (73.6) 44 (64.7) 44 (69.8) 
Hospital stay (days)† 2 (0-15) 2 (0-7) 2 (0-13) 
Complications‡    
Bladder perforation 6 (5) 0 (0) 2 (3.2) 
Rectal perforation 0 (0) 0 (0) 1 (1.6) 
Urinary tract infection 4 (3.3) 2 (2.9) 3 (4.8) 
Bladder retention 11 (9.1) 3 (4.4) 5 (7.9) 
Groin/buttock pain 3 (2.5) 1 (1.5) 1 (1.6) 
Vaginal hematoma 1 (0.8) 2 (2.9) 2 (3.2) 
Cardiovascular disease 6 (5) 2 (2.9) 2 (3.2) 
Figures are ‡Number of patients (%), *Mean ± SD and †Median (range) 
Variables not adding up to 100% represent missing values 
 
Table 7. Anatomic cure rates 
  
Anterior repair  Posterior repair   Anterior and posterior repair 
  
2 months 1 year  2 months 1 year   2 months 1 year 
Anterior 
compartment 98/121 (81%) 96/121 (79%)  NA NA  
52/63 
(83%) 
51/63 
(81%) 
Posterior 
compartment NA NA  
58/68 
(85%) 
56/68 
(82%)  
55/63 
(87%) 
54/63 
(86%) 
P<0.001 for all (comparisons with baseline) 
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Table 8. POP-Q measurements 
  
Anterior repair  Posterior repair  Anterior and posterior repair 
  Baseline 1 year  Baseline 1 year  Baseline 1 year 
Anterior 
        
Ba  2(-1 to 7) -2(-4 to 3)  -2(-3 to 1) -2(-3 to 1)  2(-1 to 8) -2(-4 to 0) 
Stage II (II to IV) I (0 to III)  I (0 to II) I (0 to II)  II (II-IV) I (0 to II) 
Middle         
C  -1(-1 to -9) -6(-10 to -4)  -3(-9 to 9) -6(-11 to -4)  2(-10 to 8) -6(-12 to -4) 
Stage I (0 to II) I (0 to II)  I (0 to IV) I (0 to II)  II (0 to IV) I (0-II) 
Posterior         
Bp  -2(-3 to 0) -2(-3 to 2)  2(-1 to 5) -3(-3 to 3)  2(-1 to 8) -3(-3 to 3) 
Stage I (0-II) I (0-II)  III (II-IV) I (0-III)  II (II-IV) I (0-III) 
Data are median (range). 
 
7.1.4 Macroscopic inflammatory assessment 
All inflammatory measurements increased postoperatively in comparison with baseline 
(Table 9). Signs of granuloma and extrusion dropped in prevalence after an initial 
increase, but the number of exposures increased to 26 of 232 cases (11%, 95% CI 7.2–
15.3%) 1 year after surgery. There was no increase in mesh-related infections at 1 year 
compared to baseline. The median severity score was 0 for all measures throughout the 
study, and most cases of mesh reactions were in the range of mild-to-moderate severity. 
Although no cases of severe inflammatory reactions were reported, the need to cover or 
remove exposed mesh during the postoperative period was reported in seven cases 
(2.8%, 95% CI 0.8 –5.2), five after anterior mesh repair and two after posterior repair. 
The remaining cases of mesh exposures were all managed conservatively using topical 
estrogen or antibiotic cream. 
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Table 10. Outcomes of the short-form Incontinence Impact Questionnaire (IIQ-7) 
 
Anterior repair Posterior repair 
Anterior and 
Posterior 
repair
 n=121 n=68 n=63 
  How does incont 
affect your: Preop 1 year Preop 1 year Preop 1 year 
Household chores  p<0.001  p<0.001  p=0.002 
Not at all 76 (63) 92 (76) 43 (63) 55 (81) 36 (57) 49 (78) 
Slightly- Mod 34 (28) 12 (10) 17 (25) 6 (13) 21 (33) 8 (13) 
Greatly 4 (3) 1 (1) 4 (6) 0 (0) 3 (5) 1 (2) 
Physical 
recreation  p<0.001  p<0.001  p<0.001 
Not at all 57 (47) 82 (68) 30 (44) 43 (63) 31 (49) 43 (68) 
Slightly- Mod 44 (36) 24 (20) 24 (35) 16 (24) 22 (35) 14 (22) 
Greatly 10 (8) 1 (1) 6 (9) 2 (3) 6 (10) 0 (0) 
Entertainment 
activities  p<0.001  p=0.02  p=0.02 
Not at all 75 (62) 94 (78) 37 (54) 46 (68) 37 (59) 48 (76) 
Slightly- Mod 31 (26) 11 (9) 16 (23) 11 (16) 13 (21) 9 (14) 
Greatly 5 (4) 1 (1) 7 (10) 3 (4) 6 (10) 0 (0) 
Ability to travel by 
car/bus >20 min  p=0.002  p=0.05  p<0.001 
Not at all 80 (66) 94 (78) 43 (63) 49 (72) 42 (67) 51 (81) 
Slightly- Mod 29 (24) 10 (8) 12 (10) 10 (15) 14 (22) 7 (11) 
Greatly 5 (4) 0 (0) 6 (9) 0 (0) 4 (6) 0 (0) 
Social activities  p<0.001  p=0.02  p=0.002 
Not at all 74 (61) 90 (74) 37 (54) 51 (75) 35 (56) 46 (73) 
Slightly- Mod 34 (28) 14 (12) 15 (22) 6 (13) 17 (27) 9 (14) 
Greatly 5 (4) 0 (0) 5 (7) 3 (4) 6 (10) 1 (2) 
Emotional health  p=0.002  p=0.01  p=0.01 
Not at all 82 (68) 89 (74) 40 (59) 52 (76) 38 (60) 41 (65) 
Slightly- Mod 28 (24) 13 (11) 13 (19) 7 (10) 14 (22) 13 (21) 
Greatly 2 (2) 0 (0) 3 (4) 0 (0) 6 (10) 2 (3) 
Feeling frustrated  p<0.001  p<0.001  p<0.001 
Not at all 69 (57) 91 (75) 30 (44) 48 (71) 30 (48) 45 (71) 
Slightly- Mod 37 (31) 13 (11) 21 (31) 11 (16) 17 (27) 12 (19) 
Greatly 5 (4) 0 (0) 5 (7) 0 (0) 9 (14) 0 (0) 
Summated IIQ-7  p=0.1  p=0.05  p=0.03 
 score Mean (SD) 3.9 (±4.9) 2.8 (±2.9) 4.3 (±5.4) 3.3 (±2.7) 5.0 (±6.0) 2.8 (±2.5) 
Figures are frequency (%). Mod (Moderately), Incont (Incontinence) 
Statistical comparison between preoperative values and 1-year follow-up using the Wilcoxon signed rank test. 
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Table 11. Outcomes of the short-form Urinary Distress Inventory (UDI-6). 
 
Anterior repair Posterior repair 
Anterior and Posterior 
repair 
 n=121 n=68 n=63 
How bothersome are 
the following 
symptoms for you? Preop 1 year Preop 1 year Preop 1 year 
Frequent urination  p<0.001  p= 0.03  p<0.001 
Not at all 30 (25) 62 (51) 20 (29) 20 (29) 8 (13) 30 (48) 
Slightly- mod 58 (48) 46 (38) 29 (43) 41 (60) 33 (52) 28 (44) 
Greatly 27 (22) 0 (0) 16 (24) 0 (0) 19 (30) 0 (0) 
Urine leakage related to urgency p<0.001  p= 0.19  p= 0.002 
Not at all 45 (37) 69 (57) 35 (51) 39 (57) 23 (37) 39 (62) 
Slightly- mod 50 (41) 47 (39) 19 (28) 23 (34) 26 (41) 20 (32) 
Greatly 19 (16) 0 (0) 5 (7) 0 (0) 8 (13) 0 (0) 
Urine leakage related to physical 
activity p= 0.18  p= 0.49  p= 0.87 
Not at all 50 (41) 59 (49) 37 (54) 36 (53) 26 (41) 30 (48) 
Slightly- mod 59 (49) 39 (32) 18 (26) 21 (31) 27 (43) 25 (40) 
Greatly 6 (5) 9 (7) 3 (4) 3 (4) 4 (6) 1 (2) 
Small amounts of 
urine leakage  p= 0.08  p= 0.98  p= 0.17 
Not at all 77 (64) 78 (64) 44 (65) 46 (68) 38 (60) 44 (70) 
Slightly- mod 33 (27) 28 (23) 16 (24) 16 (24) 15 (24) 15 (24) 
Greatly 3 (2) 0 (0) 0 (0) 0 (0) 3 (5) 0 (0) 
Difficulty emptying 
bladder  p<0.001  p= 0.02  p<0.001 
Not at all 43 (36) 76 (63) 30 (44) 33 (49) 21 (33) 40 (63) 
Slightly- mod 57 (47) 25 (21) 25 (37) 27 (40) 28 (44) 15 (24) 
Greatly 17 (14) 6 (5) 7 (10) 2 (3) 8 (13) 1 (2) 
Pain lower abdomen 
or genital area  p<0.001  p= 0.38  p= 0.02 
Not at all 85 (70) 94 (78) 48 (71) 53 (78) 41 (65) 47 (75) 
Slightly- mod 24 (20) 13 (11) 9 (13) 8 (12) 14 (22) 8 (13) 
Greatly 6 (5) 0 (0) 3 (4) 1 (1) 4 (6) 2 (3) 
Summated UDI-6 
score 
 p<0.001  p=0.03  p<0.001 
Mean (SD) 5.4 (±3.9) 2.9 (±2.7) 4.4 (±2.3) 3.3 (±2.7) 5.9 (±3.8) 3.0 (±2.6) 
Figures are frequency (%).All statistical comparisons between preoperative values and 1-year follow-up using the 
Wilcoxon signed rank test. Mod (moderately) 
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Table 12. Patient characteristics 
  
N=261 
Total no. of sexually active 
patients 
n=105 
 Total no. of non-sexually 
active patients* 
n= 133 
   
Surgical procedure   
Anterior 46 (44) 66 (50) 
Posterior 26 (25) 37 (28) 
Anterior+posterior 33 (31) 29 (22) 
Age 61.5 (±7.6 SD) 69.9 (±9.0 SD) 
Parity 2 (range 1-6) 2 (range 0-7) 
Body mass index 26.8 (±4.3 SD) 26.3 (±3.9 SD) 
Smoker   
Yes 12 (11) 11 (8) 
No 92 (88) 111 (83) 
Menopausal   
Yes 94 (89) 110 (83) 
No 7 (7) 3 (2) 
Somatic diseases   
CVD 36 (34) 64 (48) 
Thyroid dysfunction 9 (9) 21 (16) 
Asthma and COPD 11 (11) 10 (8) 
Arthrosis 6 (6) 7 (5) 
Diabetes 3 (2.9) 8 (6) 
Previous pelvic surgery   
Hysterectomy 58 (55) 64 (48) 
Prolapse 43 (41) 69 (52) 
Incontinence 8 (8) 12 (9) 
Salpingo-oopherectomy 13 (12) 23 (17) 
Other 10 (9) 7 (5) 
SD, Standard deviation. COPD, chronic obstructed pulmonary disease 
Numbers not adding up to 100% represent missing values. 
Data are n (%) unless otherwise specified 
* 23 patients did not respond to the question on sexual activity at baseline.  
 
7.2.2 Subjective outcomes 
There was an overall significant decrease in mean PISQ-12 scores when comparing 
pre- and postoperative average scores. A similar decrease was observed in all strata of 
independent variables: age at surgery, BMI, current cigarette smoking, menopausal 
status, childbirths, and concurrent surgery. Similarly, the decrease in PISQ-12 scores 
was noted regardless of anatomical postoperative stage and vaginal compartment 
(Table 13).  
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Table 13. PISQ-12 scores stratified by patient characteristics. 
 Baseline 
n= 93* 
1 year 
n= 69* 
p-value 
Overall 15.5 (±8.0) 11.7 (±6.9) p< 0.001 
Body mass index    
≤ 25 14.9 (±6.6) 12.5 (±6.2) p= 0.04 
>25 16.7 (±8.9) 11.9 (±7.2) p= 0.006 
Postmenopausal    
Yes 15.7 (±8.1) 12.0 (±7.1) p< 0.001 
No 17.4 (±8.8) 10.6 (±8.3) p< 0.001 
Smoker    
Yes 13.5 (±9.0) 12.5 (±7.8) p= 0.2 
No 16.2 (±7.9) 12.0 (±6.7) p<0.001 
Concurrent surgery    
Yes 15.3 (±7.4) 11.9 (±6.2) p= 0.2 
No 16.0 (±8.1) 12.2 (±6.8) p< 0.001 
Age    
≤ 65 16.0 (±8.4) 11.8 (±6.9) p< 0.001 
>65 15.6 (±7.0) 12.8 (±6.3) p= 0.2 
Parity    
1-2 15.6 (±8.4) 13.0 (±6.9) p= 0.008 
≥ 3 16.2 (±7.5) 10.8 (±6.0) p= 0.01 
Anterior transvaginal mesh repair     
POP-Q Stage 0-I † 13.0 (±8.9) NA 
POP-Q Stage II-III  16.9 (±8.5) 12.8 (±8.7) p= 0.01 
Posterior transvaginal mesh repair    
POP-Q Stage 0-I  † 12.3 (±5.3) NA 
POP-Q Stage II-III 15.4 (±7.8) 12.5 (±5.5) p= 0.08 
Anterior transvaginal mesh repair  15.5 (±8.7) 12.3 (±8.0) p= 0.03 
Posterior transvaginal mesh repair 15.0 (±7.8) 13.5 (±5.3) p= 0.2 
Combined anterior and posterior 
transvaginal mesh repair 
17.3 (±6.8) 10.7 (±5.5) p= 0.002 
*Number of patients where a PISQ-12 score could be calculated.  A summated score can be calculated with up to two 
missing values, after which the short form looses accuracy in predicting the full version.   
†No patients available for analysis. 
Statistical comparison between baseline and one year after surgery performed with Wilcoxon signed rank test. 
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The forward multiple logistic regression analysis showed no significant predictors for 
low (12 or less) sexual function (Table 14).  
 
Table 14. Relative risks (95% confidence intervals) for predictors of low (12 or less) 
sexual function scores 
 
Predictors RR (95% CI)
Age older than 65 years 1.5 (0.3–7.4) 
Body mass index higher than 25  2.1 ( 0.5– 8.9) 
Current cigarette smokers 8.9 (0.7–107.2) 
Postmenopausal status  3.3 (0.1– 86.2) 
More than two childbirths 0.7 ( 0.3–1.5) 
Stage II or higher anterior prolapse 
postoperatively  1.1 ( 0.6 –2.0) 
Stage II or higher posterior prolapse 
postoperatively 1.1 (0.7– 6.9) 
Other concurrent surgery  1.9 (0.8 –7.3) 
Vaginal exposure when 
characterized as present or absent 2.9 (0.8 –9.1) 
 
For the physical items, improvements were seen in ‘always fear of incontinence 
restricting sexual activity’ (82% compared with 63%, P<0.01) and ‘always avoidance 
of intercourse because of vaginal bulging’ (70% compared with 29%, p<0.001) whilst 
no significant changes were seen for ‘incontinence during sexual activity’ (62% 
compared with 56%, p=0.37) or ‘pain at intercourse’ (dyspareunia) (p=0.62 for anterior 
and P=0.13 for posterior mesh repair). Detailed results for dyspareunia are shown in 
Figures 13 and 14. Although generally non significant by themselves, there was an 
overall postoperative worsening of all behavioral– emotive and partner-related items. 
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Figure 13. Prevalence of dyspareunia after anterior transvaginal mesh repair 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
P=0.62 for statistical comparison between pre- and postoperative ordinal data using the 
Wilcoxon signed rank test. 
 
Figure 14. Prevalence of dyspareunia after posterior transvaginal mesh repair 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
P=0.13 for statistical comparison between pre- and postoperative ordinal data using the 
Wilcoxon signed rank test. 
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7.3 PAPER III 
7.3.1 Patient and control characteristics 
10 patients and 8 controls were included in the study and the subject characteristics 
between the groups differed in several aspects: patients were older, had given birth to 
more children, were all postmenopausal, more often used hormone replacement therapy 
and had a higher BMI (Table 15). One baseline patient biopsy could not be assessed 
due to lack of epithelium. Patients were analyzed as their own controls in the pre- and 
postoperative evaluations. 
 
Table 15. Descriptive group characteristics. 
 Cases 
n= 10 
Controls 
n= 8 
p-value 
Mean age (±SD) 67.1 (± 7.5) 42 (± 13.0) p=0.002 
Median parity (min,max) 2.5 (1-4) 1.3 (0-2) p=0.06 
Body mass index (±SD) 26.5 (± 4.8) 23.6 (± 4.0) p=0.5 
Menopause (%) 10 (100) 2 p<0.001 
HRT (%) 4 (40) 0 p=0.07 
Local estrogens (%) 3 (30) 0 p=0.1 
Smoking (%) 0 (0) 0 p=1.0 
Prolift    
Anterior (%) 4 (40) - NA 
Posterior (%) 2 (20) - NA 
Anterior+posterior (%) 4 (40) - NA 
Comparison on non-parametric data using Mann-Whitney U-test and for proportions 
using χ2. 
 
7.3.2 Macroscopic inflammatory assessment. 
There were no statistically significant changes in macroscopic inflammatory grading 
assessment postoperatively, although several cases of granuloma formation and 
exposure were observed (Table 18). Three cases of mild granuloma formation and 2 of 
mild exposure were detected but neither resulted in a surgical intervention. There were 
no cases of serious mesh related complications or mesh exposure/extrusion.  
 
7.3.3 Microscopic assessment 
Baseline histological counts and morphological grading in patients and controls were 
similar unless otherwise stated below. 
 
Total cell content in the subepithelial tissue 
(Table 16) At one year the total cell count decreased significantly compared with 
preoperative counts (p= 0.02). Controls had a higher total cell count than patients (p= 
0.05). 
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7.4 PAPER IV 
7.4.1 Patient characteristics 
A total 353 patients having had anterior mesh kit repair for anterior pelvic organ 
prolapse were included in this secondary analysis. Data on inflammatory response was 
available for 337/353 patients (95%) at baseline, 351/353 (99%) at 2 months and 
349/353 (99%) women at the 1 year follow-up. Mean age at surgery was 65.3 years 
(±9.6 SD), mean body mass index (BMI) was 26.5 kg/m2 (± 3.8 SD) and median parity 
was 2 (range 0-7). The procedure was performed for prolapse recurrence in 129/353 
patients (36.5%). There were 37 smokers (10.5%) and the number of women suffering 
from somatic inflammatory disease was 12 (3.4%) of which rheumatic disease was the 
predominant diagnosis (Table 19). 
 
Table 19. Patient characteristics 
  
Anterior repair using
 the Prolift® system
  n= 353  
Age (y) 65.3 ± 9.6
Parity 2 (0-7)
Body mass index 26.5 ± 3.8
Educational level* 
Compulsory school 195 (55.2)
High school 50 (14.2)
College/ university 87 (24.6)
Annual income (€)* 
Less than 10  000 52 (14.7)
10 000 - 30 000 213 (60.3)
30 000 - 40 000 15 (4.2)
More than 40 000 12 (3.4)
Smoker* 
Yes 37 (10.5)
No 311 (88.1)
Menopausal* 
Yes 292 (82.7)
No 60 (17.0)
Local or systemic hormone treatment*  
Yes 245 (69.4)  
No 18 (5.1)  
Somatic diseases  
Systemic 
inflammatory disease 12 (3.4)  
Diabetes 8 (2.3)  
Any previous prolapse 
surgery 129 (36.5)  
Data are mean ± standard deviation, median (range) or n (%) * 
Figures not adding up to 353 or 100% represent unavailable data
 49 
7.4.2 Mesh reactions 
Inflammatory reactions at baseline were attributed to mechanical prolapse devices i.e. 
pessaries. Compared to baseline, the total number of patients with any type of 
inflammatory reaction to the mesh was 31.3% (110/351, p=0.000) at 2 months follow-
up and thereafter decreased to 16.0% (56/349, p=0.001) at 1 year. Granulomas and 
exposures were the most commonly observed inflammatory reactions at 2 months. At 
the 1 year assessment compared with baseline, the number of granulomas (4.3%, 
p=0.010) showed a tendency to decrease compared with 2 months (18.8% p=0.001) 
whereas the number of exposures persisted (8.6%, p=0.003) (Table 20).  
The number of cases with infections, necrosis and mesh extrusions were very few 
and there were no significant changes at 1 year compared to baseline or 2 months 
follow-up. Aside from one severe mesh reaction, most mesh related adverse events 
were in the range of mild-moderate severity and were managed conservatively. 
Surgical intervention because of mesh exposure during the one year follow-up was 
reported in a total of 11/353 patients (3.1%): five patients in the cohort study and 6 
patients in the randomized controlled trial. No significant difference was observed 
when comparing mesh exposures at one year in patients undergoing primary or repeat 
surgery for anterior wall prolapse (7 vs. 23 exposures, p=0.15). 
 
Table 20. Macroscopic assessment of clinical inflammatory reaction to anterior 
transvaginal mesh. 
 
Pre-
operatively  2 months   1 year   
 n=337*  n=351*   n=349*   
  
No. of 
 patients  
(%) 
Median 
severity 
(range)
No. of 
patients 
(%)
Median 
severity 
(range) P-value
No. of 
patients 
 (%) 
Median 
severity 
(range) P-value
Any kind of 
reaction 21 (6.2) 110 (31.3) 0.000 56 (16.0) 0.001
granuloma  4 (1.2) 0 (0-2) 66 (18.8) 0 (0-3) 0.000 15 (4.3) 0 (0-2) 0.010
exposure 12 (3.6) 0 (0-3) 25 (7.1) 0 (0-3) 0.018 30 (8.6) 0 (0-4) 0.003
necrosis 1 (0.3) 0 (0-1) 9 (2.6) 0 (0-2) 0.017 3 (0.9) 0 (0-2) 0.201
infection 3 (0.9) 0 (0-2) 7 (2.0) 0 (0-2) 0.028 1 (0.3) 0 (0-2) 0.584
extrusion 1 0 (0-1) 3 (0.9) 0 (0-2) 0.109 7 (2.0) 0 (0-2) 0.093
Statistical comparison with preoperative values for 2 months and 1-year follow-up using the Wilcoxon signed rank 
test. *Figures not adding up to 353 represent unavailable data 
 
7.4.3 Risk factors for exposures 
In the stratified analysis, the number of exposures seen at one year was greater for 
smokers than for non smokers (p= 0.02) and for patients suffering from somatic 
inflammatory disease compared to non sufferers (p= 0.03) (Table 21). Mesh exposures 
occurred among 7/37 smokers but showed no clear pattern with regard to those who 
smoked 0-5 cigarettes/day (2 exposures), 5-10 cigarettes/day (2 exposures), 10-20 
cigarettes/day (2 exposures) or >20 cigarettes/day (1 exposure). There were no 
significant differences in the number of exposures in relation to age, parity, smoking, 
BMI, postmenopausal status, concurrent surgery or previous prolapse surgery. 
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Table 21. Mesh exposures at 1 year stratified by patient characteristics 
 
  
No. of 
patients at 
one year 
Patients with 
exposures at 
one year % P-value
      
Overall 349 30 8.60
Age  
≤ 65 182 15 8.24 0.66
>65 167 15 8.98
Parity  
≤ 2 215 14 6.51 0.08
>2 134 16 11.94
Body mass index 
≤ 25 152 12 7.89 0.75
>25 197 18 9.14
Postmenopausal 
Yes 288 26 9.03 0.60
No 60 4 6.67
Smoker  
Yes 37 7 18.92 0.02
No 307 23 7.49
Concurrent surgery 
Yes 38 4 10.53 0.63
No 311 26 8.36
Somatic inflammatory disease 
Yes 12 3 25.00 0.03
No 264 20 7.58
Diabetes  
Yes 8 0 0.00 0.40
No 264 23 8.71
Previous prolapse surgery 
Yes 126 7 5.56 0.98
No 65 4 6.15  
Figures not adding up to 349 or 100% represent unavailable data 
Statistical comparison of exposures at 1 year grouped by patient  
characteristics using the Mann-Whitney U test  
 
Uni- and multivariate logistic regression analysis for risk factors used age (>65 years), 
smoking (yes/no), postmenopausal status (yes/no), body mass index (>25kg/m2), parity 
(>2 children), and somatic inflammatory disease as independent univariate variables 
(Table 22). Following adjustment for age, parity, body mass index, and menopausal 
status, significant associations with mesh exposures remained at 1 year for smoking 
(OR 3.48, 95% CI 1.18-10.28) and somatic inflammatory disease (OR 5.11, 95% CI 
1.17-22.23). The non-significant association between parity and exposures in the 
univariate analysis became significant when adjusting for the other independent 
 
variables. 
inflammat
 
Table 22. 
 
  
Age >65 year
Parity>2 child
BMI>25 
Menopause 
Smoking 
Somatic infla
*Multivariabl
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8 DISCUSSION 
 
8.1 SUBJECTIVE AND OBJECTIVE CLINICAL OUTCOMES 
Trocar guided transvaginal mesh surgery for pelvic organ prolapse is associated with 
satisfactory subjective and objective clinical outcomes at 1 year. Anatomic cure rates 
ranged between 79-86% and the combined anterior and posterior procedure was 
associated with the most effective restoration of vaginal support. This could be a result 
of the added support provided to the upper vagina by the posterior procedure. Since 
more than half of all elderly women show signs of stage II prolapse,(1) the definition of 
anatomic success as stage 0-I used in this study can be debated. Had we used a more 
lenient definition, success rates would of course have been even higher. The superior 
overall anatomic cure rates of 95% observed in a study by Fatton et al may be 
explained by differences in study design, follow up time, and prolapse classification 
system.(11)  
Compared with traditional pelvic organ prolapse repair, our study resulted in 
improved anatomic cure rates for anterior repair,(59, 95, 96) but similar cure rates for 
posterior repair,(97-99) This suggests that use of mesh provides a greater advantage in 
anterior repair whereas addition of mesh is less advantageous with regard to restoration 
of posterior vaginal topography. Improvements in subjective outcomes for all operated 
vaginal compartments were observed and sustained at the one year follow-up. Although 
patient satisfaction does not necessarily correlate to anatomic cure,(100, 101) we found 
an association between anatomic improvement and ameliorated symptoms. 
The postoperative improvements in lower urinary tract dysfunction observed in this 
study were statistically significant, yet the clinical significance can be debated since the 
magnitude of the improvements were less than half of the standard deviations of the 
baseline values. The lack of improvement observed for stress urinary incontinence may 
theoretically be due to an overcorrection of the anterior vaginal wall and bladder neck 
caused by the mesh technique as discussed previously and corroborates findings in 
previous studies.  
The number of adverse events observed in this study is comparable to other 
studies.(9, 80) The number of exposures persisted at one year, which is also comparable 
to other studies,(72, 102) although the number of surgical interventions needed for 
treatment of mesh exposures were fewer. A possible explanation for this was the 
routine use of preoperative topical estrogen in all patients before surgery and after the 
two month follow-up included in the study protocol. Furthermore the low rate of 
serious mesh complications can be attributed to the strict aseptic handling of the mesh, 
change of gloves in mid-surgery, use of intra operative antibiotic prophylaxis and the 
supervised hands-on training for all participating surgeons before study start.   
The satisfactory subjective and objective outcomes observed in this prospective 
multicenter cohort study with a near 90% follow up rate, are comparable to results 
observed in randomized trials.(78, 103) 
 
8.2 SEXUAL DYSFUNCTION  
Sexual dysfunction scores deteriorated one year after trocar guided transvaginal mesh 
kit repair of pelvic organ prolapse. The deterioration was primarily observed for scores 
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in behavioral-emotive and partner-related items though not for dyspareunia in specific 
which was somewhat surprising. Although de Tayrac et al. showed a 13% increased 
rate of de novo dyspareunia following mesh repair, several studies (ours included) have 
not shown significantly increased rates of dyspareunia.(104) The divergent results on 
dyspareunia could be explained by differences in surgical techniques, differences in 
mesh texture or composition and use of different instruments to measure the rate of 
dyspareunia.  
A negative trend in sexual scores was noted regardless of categorization of patient 
characteristics. Baseline scores were, however, fairly low to begin with and a 15% 
deterioration in sexual function scores is clinically difficult to interpret. In comparison 
to a study by Sentilhes et al.,(104) the women in our study had considerably lower 
baseline sexual function scores. Because there is a dirth of normative PISQ sexual 
function scores in various age categories of women we cannot say if our study 
population had a poorer sexual function as compared to the general population. If this is 
the case, some degree of selection bias was probably involved and surgeons may have 
been less inclined to include women with normal sexual function into the study. Even 
so not all women deteriorated in sexual function and some actually moved from poor 
sexual function in a positive direction after surgery. This corroborates studies which 
suggest that restoration of vaginal topography may actually improve sexual function in 
some patients.(105)  
No specific predictors of poor sexual function related to surgery were found and 
although a post hoc power analysis indicated an adequate sample size for overall 
scores, specific independent variables may not have been adequately powered. The 
inclusion and exclusion criteria in our study add to the internal validity but one should 
bear in mind that considering our population characteristics our findings may not be 
generalised to pre menopausal or nulliparous women. 
Sexual function scores in the present study were similar regardless of anatomic 
outcomes, and objective anatomical cure showed no correlation with sexual function. 
This has also been shown for traditional repair without mesh,(106) although others 
have found a positive association between anatomical success and sexual function after 
prolapse correction with mesh.(104, 105, 107) No concurrent continence procedures 
were performed at the time of prolapse repair in this study so any improvements in 
sexual function could not be explained by surgically improved continence. 
It is known that a positive body image and self esteem are associated with better 
sexual function,(108) and although some studies have shown positive sexual results in 
general after vaginal surgery,(109, 110) studies focusing on emotional and partner 
related aspects are scarce. Future studies should focus not only on physical aspects of 
sexual dysfunction after prolapse surgery but also behavioral, emotional and partner 
related issues. 
The risk of deteriorated sexual function seen in this study is corroborated by a recent 
randomized study by Altman reporting a greater risk of dyspareunia in the mesh group 
compared to the traditional repair group (7.3% vs 2%). However, another recent 
randomized study by Withagen saw no significant difference in dyspareunia between 
the groups (8% vs 10%).(78, 103)  
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8.3 HISTOLOGICAL INFLAMMATORY RESPONSE 
A certain degree of inflammatory response is to be expected when placing a foreign 
body into the human body, but this is to our knowledge the first human in vivo study 
assessing inflammatory reactions to large sized mesh for pelvic organ prolapse. 
Although previous studies have been performed in rodents,(111) it is questionable 
whether data can be extrapolated to humans considering the unique human vaginal 
environment and dynamics. Human histological studies on the other hand are ethically 
limited by the number of participants. This study was novel and pilot like in nature 
similar to a previous study on mesh used for sling procedures,(6) and therefore no 
power analysis was performed and patients and controls were not matched according to 
age, parity or menopause.  
We found a postoperative increase in macrophages and mast cells at one year after 
surgery suggesting an activation of a persistent cellular foreign body response. 
Phagocytosis of foreign body material or microbes is the primary role of macrophages 
together with antigen presentation and secretion of cytokines. Mast cells are major 
effector cells of hypersensitivity reactions, reside adjacent to blood vessels and 
degranulate inflammatory mediators such as histamine. The increase in 
semiquantitative grading of inflammatory cell infiltration, although non-significant, 
also suggests a mild inflammatory response to the mesh. This is also in agreement with 
rat studies suggesting that type I mesh causes a mild inflammatory reaction.(112) Cells 
actived primarily in infectious responses, such as lymphocytes, were unaltered 
postoperatively indicating that the histologic reaction was of a non infectious type. The 
largely unchanged epithelial measurements also corroborates the finding of an 
inflammatory response of low intensity and corresponds to the few cases of severe 
clinical mesh reactions in the larger study.(113) 
A slight decrease in total cell count and number of fibroblasts was observed one year 
postoperatively suggesting that healing and scar formation was completed. No adverse 
influence on connective tissue metabolism was found as reflected by the statistically 
unchanged elastin area fraction and collagen density postoperatively. Mesh- host issue 
integration could not be assessed as no direct mesh biopsies were taken from the mesh 
in order to avoid risks of infection or exposure. 
Elastin area fraction counts were higher in women with pelvic organ prolapse 
compared to controls, suggesting an etiologic role for elastin in the development of 
pelvic organ prolapse. Total cell counts and inflammatory cell infiltration also differed 
between the two groups and an explanation could be the differences in population 
characteristics such as age and menopause. However, cell counts in specific were 
similar in patients and controls so it is plausible that the observed increase in 
macrophages and mast cells was attributed to mesh reactions. This is in concurrence 
with other reports,(112, 114) and is strengthened by the use of blinded histopathologist. 
The macroscopic clinical inflammatory grade was in agreement with the 
microscopic findings suggesting a satisfactory biocompatibility of large transvaginal 
mesh used for pelvic organ prolapse. That said, a persistent mild foreign body reaction 
was observed and the long-term effects remain unknown.  
 
8.4 PREDICTORS OF MESH EXPOSURES 
The prevalence of mesh exposures (and granuloma) increased one year after surgery 
and increased significantly in women with more than 2 children, cigarette smokers and 
 55 
somatic inflammatory disease. In comparison to clinical studies, register based 
assessments of the prevalence of exposures and other complications pertaining to 
prosthetic surgical prolapse repair have so far been limited by the lack of information 
on the total number of performed procedures. Strengths of the present study include the 
prospective study design, the uniform surgical protocol, the low number of concomitant 
procedures and a homogenous outcome measure. The overall exposure rate was 
consistent with those reported by other investigators.(115) The relatively high exposure 
rates seen in the study by Nieminen et al. may partly be explained by the placement of 
mesh between the endopelvic fascia and mucosa instead of beneath the fascia.(116)  
The association between exposures and multiparity may be an effect of vaginal 
tissues losing resilience after childbirth and as a result are susceptible to mesh 
exposure. However, the finding should be interpreted with caution since multiparity 
was not a risk factor in the stratified or univariate analysis which may indicate a chance 
finding due to insufficient sample size or large within group variation. 
The proportion of smokers in our population was comparable to Swedish population 
statistics for women over 64 years.(117) It is known that smoking is associated with 
increased post operative morbidity,(118) and in a recent Swedish trial, smoking 
cessation preoperatively decreased the risk of acquiring post operative 
complications.(119) Cundiff and Lowman found smoking to be a risk factor for mesh 
exposure in patients undergoing abdominal sacral colpopexy.(120, 121) Studies on the 
effects of smoking in transvaginal mesh surgery are few,(72) but largely concur with 
the results of the present study. 
Postoperative wound healing,(122, 123) connective tissue metabolism, collagen 
synthesis and epithelial regeneration,(124) have all been shown to be affected by 
smoking, as well as tissue oxygenation, peripheral vasoconstriction, immune cell 
response,(125, 126) and the progesterone estrogen ratio,(127) All of these factors may 
influence mesh biocompatibility and thus be adversely affected by tobacco smoking. 
Previous studies suggest that the risk of mesh exposures is influenced by age, BMI,(72, 
128) concomitant hysterectomy and surgical incision in proximity to the mesh.(73)  
Vaginal epithelial maturity may influence reactions to implants. The use of pre- and 
postoperative local estrogens in both studies aimed to improve the condition of the 
vaginal epithelium but no specific measurements of epithelial maturity were performed. 
Studies using karyopycnotic indexing or vaginal pH may provide additional 
information on epithelial reactions to synthetic mesh.  
Although somatic inflammatory diseases such as rheumatoid arthritis, Sjögren’s 
disease and lupus erythematosus have more or less different pathoetiologies, they also 
have similar characteristics such as multiple organ involvement, afflicted connective 
tissues and underlying autoimmune mechanisms. These traits accompanied by 
immunosuppressant medications may prolong wound healing and influence human 
host-vs-implant reactions. The number of patients with somatic inflammatory disease in 
our study was small (indicated by wide confidence intervals) and the association is in 
need of corroboration in further studies. 
It remains to be determined if the rather simple intervention of pre- and 
perioperative smoking cessation, may contribute to a decrease in the rate of mesh 
complications when used for pelvic reconstructive surgery. In any case, smoking 
cessation should be integrated as one component in a broader prevention strategy to 
reduce mesh complications. 
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9 CONCLUSIONS 
 
The specific aims and conclusions were: 
 
1. Aim: To prospectively investigate the clinical outcomes one year after pelvic 
organ prolapse repair using a trocar-guided mesh kit. (Paper I) 
 
Conclusion: Standardized trocar-guided transvaginal mesh techniques can be 
performed in a multicenter setting with a relatively low rate of serious surgical 
complications and with satisfactory subjective and objective outcomes. 
 
2. Aim: To prospectively study the sexual outcomes one year after pelvic organ 
prolapse repair using a trocar-guided mesh kit. (Paper II) 
 
Conclusion: There is a risk for sexual dysfunction based on emotional-
behavioral and partner- related issues after transvaginal mesh kit repair of pelvic 
organ prolapse. 
 
3. Aim: To investigate the histological inflammatory response one year after 
transvaginal pelvic organ prolapse repair using mesh. (Paper III) 
 
Conclusion: There is a mild but persistent histological foreign body reaction 
after pelvic organ prolapse surgery with large macroporous monofilament 
polypropylene mesh.   
 
4. Aim: To assess potential risk factors associated with the development of 
exposures one year after transvaginal pelvic organ prolapse repair using mesh. 
(Paper IV) 
 
Conclusion: Smoking, multiparity and somatic inflammatory diseases are 
possible risk factors for mesh exposures after trocar guided anterior mesh kit 
repair for pelvic organ prolapse.  
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10 POPULÄRVETENSKAPLIG SAMMANFATTNING 
Framfall är en benign sjukdom som medför att slidans väggar och organen innanför 
buktar in i och ibland ut ur slidan. Hos dessa kvinnor har vaginas stödjestrukturer 
förlorat sin hållbarhet och spänst. Symptomen inkluderar tyngd- tryck- eller 
utfyllnadskänsla i vagina men kan även innefatta symptom från bäckenorganen som 
blåstömningssvårigheter, överaktiv blåsa, sexuell dysfunktion samt 
tarmtömningssvårigheter. Symptomen leder ofta till en betydande försämring av den 
drabbade kvinnans livskvalitet. Omkring 50% av alla kvinnor som har fött barn har 
någon form av framfall, och livstidsrisken att genomgå operation pga framfall eller 
urininkontinens har estimerats till ca 11%.  
Det är inte helt klarlagt vad som orsakar framfall men kopplingar finns till 
graviditet, barnafödande, tillstånd med ökat buktryck (t.ex. fetma, kronisk obstruktiv 
lungsjukdom, tungt arbete) samt ärftliga faktorer. Standardbehandlingsmetoden är en 
kirurgisk teknik där man försöker återskapa stödet för vagina. Metoden har funnits i 
över 100 år men har visat sig ge otillfredsställande långtidsresultat och på grund av 
recidiv tvingas upp emot 30-50% av alla kvinnor som genomgår traditionell 
framfallskirurgi att genomgå ytterligare ingrepp. 
Vid ljumskbråckskirurgi och urininkontinenskirurgi har kraftigt förbättrade 
operationsresultat uppnåtts vid användning av syntetiskt polypropylennät som stöd för 
den sviktande vävnaden. Till följd av detta föreligger en utbredd användning av 
syntetiskt implantat även vid framfallsoperationer trots att man ännu inte bevisat 
eventuella fördelar för användning i detta område. Betingelserna i slidan är annorlunda, 
slidan har en annan miljö och funktion än ljumsken, och nätet är mycket större än det 
som används vid inkontinenskirurgi. Därför kan man inte förbehållslöst anta att 
implantat är lika framgångsrika vid framfallskirurgi som vid ljumskbråcks- eller 
inkontinenskirurgi. Det är hittills ont om studier som har studerat resultaten av 
framfallskirurgi med syntetiska nät vid framfall och studierna i denna avhandling 
ämnar belysa både kliniska och histologiska utfall vid framfallsoperation med syntetiskt 
nät. 
I den första studien i denna avhandling har flera kliniker i de nordiska länderna 
samarbetat i en prospektiv kohortstudie. 261 kvinnor med framfall inkluderades och 
genomgick operation med ett syntetiskt nät där nätet placerades med hjälp av 
metalledare för att åtgärda framfallet i framvägg, bakvägg eller både och. De 
undersöktes gynekologiskt och fick fylla i enkäter angående prolaps och 
inkontinenssymptom samt livskvalitet före operation, efter 2 månader och 1 år. Vi fann 
att det anatomiska resultatet var bra efter 1 år, att kvinnorna var nöjda med 
operationsresultatet, och att livskvaliteten hade förbättrats dock inte beträffande 
symptom som rörde ansträngningsurininkontinens. I samband med operation noterades 
en relativt låg frekvens av allvarliga komplikationer men vid ett år konstaterades att 
nätet hade blivit exponerat i slidan hos drygt en tiondel av patienterna.  
Den andra studien använde sig av samma patientgrupp som ovan men kvinnorna 
fick i stället besvara en enkät beträffande sexuella vanor före operation och efter 1 år. 
Vi fann att bara 105 av kvinnorna var sexuellt aktiva från början och efter operation var 
84 sexuellt aktiva. Dessa kvinnor var något yngre än de som inte var sexuellt aktiva 
men i övrigt fanns det inga skillnader mellan grupperna. Efter operation såg vi en 
försämring i sexuell funktion oavsett vikt, ålder, antalet barn, framfallsnivå, vilken del 
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av slidan som opererades eller operationsresultat. Enstaka kvinnor förbättrades i sexuell 
funktion men generellt skedde en försämring där den största försämringen sågs i frågor 
rörande beteende, känslor samt partnerrelaterade frågor. Ingen försämring sågs för 
frågor rörande smärta vid sexuell aktivitet (dyspareuni). 
I den tredje studien undersöktes slidans cellulära reaktion på framfallsnät. Från 
Danderyds Sjukhus i Stockholm inkluderades 10 kvinnor som hade framfall och som 
skulle genomgå operation med nät samt 8 kvinnor utan framfall som var planerade för 
annan kirurgi i bäckenet. Alla genomgick gynekologisk undersökning och 
vävnadsprovtagning från slidväggen i samband med operation. De 10 kvinnorna som 
framfallsopererades genomgick även gynekologisk undersökning och 
vävnadsprovtagning från slidväggen i lokalbedövning efter 1 år. Vävnadsproverna  
analyserades histologiskt och vi fann att jämfört med före operation förelåg en ökad 
låggradig inflammation vid 1 år. Mängden stödjevävnad och epiteltjocklek hade inte 
förändrats, dock förelåg en skillnad jämfört med de friska kontrollerna vilket tyder på 
att det möjligen finns en koppling mellan framfall och stödjevävnad. De histologiska 
fynden stämde överens med de tecken på inflammation och nätexponering som sågs vid 
den gynekologiska undersökningen. 
Den fjärde studien fokuserade på exponering eller utträngning av nätet och vilka 
faktorer som kan tänkas påverka denna risk. De patienter från första studien som hade 
genomgått operation på främre slidväggen samt samtliga patienter från en senare 
randomiserad studie som också hade opererats med nät i främre slidväggen 
inkluderades, totalt 349 patienter. Nätexponering sågs hos 8,6% av patienterna och 
vidare analys identifierade rökning, reumatisk sjukdom och fler än två barn som 
riskfaktorer för exponering.  
De fyra studierna i denna avhandling har funnit att standardiserade 
framfallsoperationer med nät kan genomföras med relativt få allvarliga kirurgiska 
komplikationer och med tillfredsställande subjektiva och objektiva resultat. Det 
föreligger dock en risk för att den sexuella funktionen försämras framförallt beträffande 
frågor rörande beteende, känslor samt partnerrelaterade frågor. Nätreaktioner kan 
förklaras av en inflammatorisk cellulär reaktion snarare än infektionrelaterade cellulära 
reaktioner. Vi har också sett att rökning, rheumatiska sjukdomar och fler än två barn 
ökar risken för nätkomplikationer. Beslutet om operation för framfall är komplext och 
måste väga in all tillgänglig information om kvinnans symptom, framfallets natur och 
de olika framfallsingreppens för- och nackdelar i både det korta och långa loppet. Vid 
användning av nät vid framfallsoperation bör därför potentiella risker och vinster 
noggrant övervägas. 
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13 APPENDIX 
13.1 QUESTIONNAIRES PAPER I 
 
Urogenital Distress Inventory  - Short form (UDI-6)   
Do you experience, and, if so, how much are you 
bothered by  
(0) not 
at all 
(1) 
slightly 
(2) 
moderately 
(3) 
 greatly 
1) Frequent Urination? 
    
2) Urine leakage related to the feeling of urgency? 
    
3) Urine leakage related to physical activity, coughing 
or sneezing?     
4) Small amounts of urine leakage (drops)? 
    
5) Difficulty emptying your bladder? 
    
6) Pain or discomfort in the lower abdominal or genital 
area?     
         
Incontinence Impact Questionnaire - Short form (IIQ-7)    
Has urine leakage and/or prolapse affected your  (0)not 
at all 
(1) 
slightly 
(2) 
moderately 
(3)  
greatly 
1) Ability to do household chores (cooking, 
housecleaning, laundry)?        
2) Physical recreation such as walking, swimming, or 
other exercise?        
3) Entertainment activities (movies, concerts, etc.)? 
       
4) Ability to travel by car or bus more than 30 minutes 
from home?        
5) Participation in social activities outside your home? 
       
6) Emotional health (nervousness, depression etc.)? 
       
7) Feeling frustrated? 
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13.2 QUESTIONNAIRE PAPER II 
Pelvic Organ Prolapse/Urinary Incontinence Sexual Function Questionnaire 
(PISQ-12) 
Following are a list of questions about you and your partner’s sex life. All information is strictly confidential. Your 
confidential answers will be used only to help doctors understand what is important to patients about their sex lives. 
Please check the box that best answers the question for you. While answering the questions, consider your sexuality 
over the past six months. Thank you for your help. 
1. How frequently do you feel sexual desire? This feeling may include wanting to have sex, planning to 
have sex, feeling frustrated due to lack of sex, etc. 
       Always (0)         Usually (1)         Sometimes (2)        Seldom (3)        Never (4) 
 
2. Do you climax (have an orgasm) when having sexual intercourse with your partner? 
       Always (0)         Usually (1)         Sometimes (2)        Seldom (3)        Never (4) 
 
3. Do you feel sexually excited (turned on) when having sexual activity with your partner? 
       Always (0)         Usually (1)         Sometimes (2)        Seldom (3)        Never (4) 
 
4. How satisfied are you with the variety of sexual activities in your current sex life? 
       Always (0)         Usually (1)         Sometimes (2)        Seldom (3)        Never (4) 
 
5. Do you feel pain during sexual intercourse? 
       Always (0)         Usually (1)         Sometimes (2)        Seldom (3)        Never (4) 
 
6. Are you incontinent of urine (leak urine) with sexual activity? 
       Always (0)         Usually (1)         Sometimes (2)        Seldom (3)        Never (4) 
 
7. Does fear of incontinence (either stool or urine) restrict your sexual activity? 
       Always (0)         Usually (1)         Sometimes (2)        Seldom (3)        Never (4) 
 
8. Do you avoid sexual intercourse because of bulging in the vagina (either the bladder, rectum or vagina 
falling out)? 
       Always (0)         Usually (1)         Sometimes (2)        Seldom (3)        Never (4) 
 
9. When you have sex with your partner, do you have negative emotional reactions such as fear, disgust, 
shame or 
       Always (0)         Usually (1)         Sometimes (2)        Seldom (3)        Never (4) 
 
10. Does your partner have a problem with erections that affects your sexual activity? 
       Always (0)         Usually (1)         Sometimes (2)        Seldom (3)        Never (4) 
 
11. Does your partner have a problem with premature ejaculation that affects your sexual activity? 
       Always (0)         Usually (1)         Sometimes (2)        Seldom (3)        Never (4) 
 
12. Compared to orgasms you have had in the past, how intense are the orgasms you have had in the past 
six months? 
        Much less intense (4)           Less intense (3)           Same intensity (2) 
        More intense (1)        Much more intense (0) 
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13.3  PARTICIPATING CENTERS 
The Nordic Transvaginal Mesh group includes the follow study centers: 
 
TVM 2  
Sweden  
  
Danderyd Hospital, Stockholm Västerås Hospital, Västerås 
Kristiansstad Hospital, Kristiansstad Skaraborg Hospital Skövde, Skövde 
S: t Göran Hospital, Stockholm Ystad Hospital, Ystad 
Linköping University Hospital, Linköping Uppsala University Hospital, Uppsala 
Sahlgrenska University Hospital, 
Göteborg 
Vrinnevi Hospital, Norrköping  
South Hospital, Stockholm 
Örebro University Hospital, Örebro Halmstad Hospital, Halmstad’ 
   
  
Finland  
   
Turku University Hospital, Turku Helsinski University Central Hospital 
Päisät-Hämes Central Hospital,  Lahti  Lohja Hospital, Lohja.  
Jorvi Hospital, Espoo  
  
   
Denmark  
  
Skejby Hospital, Skejby  
Nyköbing Hospital, Nyköbing  
  
  
Norway  
  
Akershus University Hospital, Ahus Haukeland Hospital, Bergen 
Gjøvik Hospital, Gjøvik Asker & Bærum Hospital, Bærum 
Kongsberg Hospital, Kongsberg Regional Hospital in Tromsø, Tromsø.   
Rikshospitalet, Oslo  
   
TVM 3 
  
Sweden  
  
Danderyd University Hospital, Stockholm Hudiksvall Hospital, Hudiksvall 
Uppsala Academic Hospital, Uppsala Karlstad Hospital, Karlstad 
Sahlgrenska University Hospital, 
Gothenburg 
Sunderby Hospital, Luleå  
Karlskoga Hospital, Karlskoga 
South Hospital, Stockholm Södertälje Hospital, Södertälje 
S:t Göran Hospital, Stockholm Örebro University Hospital, Örebro 
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Västerås Hospital, Västerås Värnamo Hospital, Värnamo 
Ystad Hospital, Ystad Västervik Hospital, Västervik 
Skaraborg Hospital Skövde, Skövde NÄL Hospital, Trollhättan 
Vrinnevi Hospital, Norrköping Borås Hospital, Borås 
Sundsvall Hospital, Sundsvall  
Linköping University Hospital, Linköping
Karolinska University Hospital Huddinge, 
Stockholm 
Kristiansstad Hospital, Kristiansstad Karslkrona Hospital, Karlskrona 
Capio Läkargruppen Örebro, Örebro Höglandssjukhuset, Eksjö 
Halmstad Hospital, Halmstad  
   
  
Finland  
  
Hyvinkää Hospital, Hyvinkää  
Jorvi Hospital, Espoo 
Central Finland Central Hospital, 
Jyväskylä 
Lohja Hospital, Lohja Kotka Hospital, Kotka 
Porvoo Hospital, Porvoo  
Åbo Hospital, Åbo 
South Carelian Central Hospital, 
Lappeenranta 
Lapland Central Hospital, Rovaniemi  
   
  
Denmark  
  
Skejby Hospital, Skejby  
  
  
Norway  
   
Kongsberg Hospital, Kongsberg Namsos Hospital, Namsos 
Rikshospitalet, Oslo S:t Olav Hospital, Trondheim 
Haukeland Hospital, Bergen Levanger Hospital, Levanger 
Bærum Hospital, Bærum Innlandet Hospital, Brumunddal 
The Regional Hospital in Tromsø, Tromsø Ringerike Hospital, Hønefoss 
Akershus University Hospital, Ahus Førde Hospital, Førde 
Telemark Hospital, Skien Sørlandet Hospital, Flekkejord 
Stavanger University Hospital, Stavanger  
 
  
